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Summary 
Summary  
Microglial cells are the resident macrophages of the central nervous system (CNS) 
and thus form the interface between the neural parenchyma and the immune system. 
Although little is known about microglia in the normal CNS, it is obvious that they are 
quickly activated in all acute pathological events that might affect the CNS. In this study, the 
role of signal regulatory protein-β1 (SIRPβ1) in microglia function was investigated by 
analyzing the effect of SIRP’s engagement on phagocytosis, inflammatory responses as well 
as on intracellular signalling in microglia with specific monoclonal antibodies (mAbs).  
The signal regulatory proteins (SIRPs) are a family of transmembrane glycoprotein 
that are mainly involved in signal transduction cascade and belong to the immunoglobulin 
(Ig) superfamily. These proteins are expressed in the hematopoietic cells including 
granulocytes, monocytes, dendritic cells, lymphocytes and the CNS. Although the 
extracellular domains of SIRPs are highly similar, classical motifs in the cytoplasmic or 
transmembrane domains distinguish them as either activating (β) or inhibitory (α) isoforms.  
The C-terminal intracellular domains of the SIRPα subfamily contain relatively long 
amino acid sequences (110aa for SIRPα1) that include four tyrosine residues to form two 
immunoreceptor tyrosine-based inhibition motifs (ITIM). Conversely, SIRPβ1 subfamily 
contains members that have a short intracellular domain containing only a few amino acids 
(4aa for SIRPβ1). Despite a short cytoplasmic tail, SIRPβ1 was reported to physically 
associate with the immunoreceptor tyrosine-based activation motif (ITAM) containing 
adaptor protein DAP12 in other cell types under the mechanism for signal transduction and 
regulation of transmigration. SIRPβ1 as well as TREM2 are associated with DAP12 
activating molecule and are expressed in microglia. We have shown that microglial SIRPβ1 
plays an important role in removal of apoptotic membrane fragments without induction of 
inflammation. Moreover relation of phagocytosis by SIRPβ1signal has been recently reported 
in macrophage (JBC). 
Functional aspect of SIRPβ1 with respect to ligands is still unknown. We are 
interested to know how extracellular ligands for SIRPβ1 might regulate cellular function. 
Protein expression of SIRPβ1 in microglial cells or splenocytes of brain, spinal cord and 
spleen from 7-8 weeks old mice (n=12) (EAE animal model) and from 12 months old APP 
transgenic mice (n=6) was analyzed by immunohistochemistry with a purified antibody 
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directed against SIRPβ1 (SIRPβ-80 and SIRPβ-84 monoclonal antibodies). Gene transcript 
levels of SIRPβ1 and DAP12 significantly increased in the spinal cord of mice with induced 
EAE as well as in the brain of APP mice. Totally, SIRPβ1 was detected in microglial cells or 
splenocytes of all organs investigated with its higher expression level in the spleen. Double 
labelling with antibodies directed against SIRPβ1 and microglia marker Iba1 (rabbit, 1/200; 
Wako, Japan) confirmed the microglial structure of the cells, positive stained for SIRPβ1. 
To study microglial SIRPβ1 function, we used lentiviral RNA interference technique. 
Our hypothesis is that like TREM2, SIRPβ1 takes part in maintenance of CNS 
microenvironment by clearance of apoptotic cells without induction of inflammation. 
Microglial activation has been increasingly recognized to contribute to the 
pathogenesis of several neurodegenerative diseases. Our study suggests that the SIRPβ1 
associated with its signalling molecule DAP12 and its stimulation induced phosphorylation 
of the ITAM motifs that leads to phagocytosis and over-activated microglia in the 
neurodegenerative disease state. This finding has broad reaching implications, as several 
pathological hallmark proteins associated with neurodegenerative disease, such as myelin, 
melanin, prions, and amyloid β are reported to be phagocytized by microglia and ongoing 
research in our group is showing SIRPβ1 mediates the evidence of microglial phagocytosis. It 
has also been shown that dying neurons, splenocytes, amyloid β and myelin are phagocytized 
by microglia, suggesting that SIRPβ1 mediated phagocytosis could be a mechanism of 
ongoing response to neurodegeneration. SIRPβ1 has not long been defined as a major 
contributing factor to multiple neurodegenerative diseases. 
 In summary, our results demonstrate that microglial SIRPβ1 and its associated 
signalling molecule DAP12 are involved in phagocytosis and that deficiency of SIRPβ1 
results in diminished microglial uptake of apoptotic neurons, splenocytes, Aβ-peptide and 
myline. Thus, understanding the role of SIRPβ1 mediated phagocytosis in the 
neurodegenerative process may help to elucidate the difference between normal microglial 
homeostasis and the disease state, offering hope for the generation of novel therapeutic 
compounds. 
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Introduction 
1. Introduction  
Central nervous system (CNS) epitomizes the largest part of the nervous system. 
Together with the peripheral nervous system, it has an essential elementary role in the 
control of behaviour. The CNS is contained within the dorsal cavity, with the brain in the 
cranial subcavity and the spinal cord in the spinal cavity. There are two main well-
defined classes of cells in the nervous system: nerve cell (neuron) and glial cells (glia). 
Further focus will be on the glial cells, which comprise a major part of my study. 
Neurons, the fundamental functional unit of the nervous system, were first 
recognized in the early 20th century by the Spanish anatomist Santiago Ramony Cajal. 
Cajal proposed that neurons are discrete cells that communicated with each other via 
specialized junctions or spaces. He also hypothesized that individual cells recognize each 
other and transmit signals and that signalling between few interconnected cells never 
produce a simple behaviour. Nerve cells are main signalling units of the CNS. A typical 
neuron has four defined regions: the cell body, dendrites, axon and the presynaptic 
terminals. The cell body (soma) is the metabolic centre of the cell. It contains the nucleus, 
which stores the genes of the cells as well as endoplasmic reticulum, an extension of the 
nucleus where the cell proteins are synthesized. The cell body usually gives rise to two 
kinds of processes: several short dendrites and one long tubular axon. Near its ends 
tubular axon divides into fine branches that form communication sites with other 
neurons. The points where two neurons interact or communicate are known as synapses. 
Those releasing the signal are called presynaptic cells. Neurons constitute about a half the 
volume of the CNS in vertebrates and glial cells make up the rest (Banati, 2003).  
Glial cells form a structural and functional network with complex cell-cell 
communication pathways that enable fast and slow signalling amongst themselves as well 
as with neurons. They exert regulatory influence on normal synaptic transmission and 
alter it in diseased conditions. It is becoming increasingly clear that an understanding of 
brain function in diseased conditions requires a better account of the highly plastic, 
disease-associated changes in glial physiology in vivo. Particularly microglia, the brain’s 
ubiquitous but normally inconspicuous immune effector cells are prominently involved in 
many brain diseases. They respond rapidly and in a highly confined territorial way to 
subtle, acute and chronic pathological stimuli. Detection of microglial activation provides 
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diagnostically useful formal parameters of disease, such as the accurate spatial 
localisation, disease progression and the secondary neurodegenerative or adaptive 
changes remote from the primary site of disease. The latter has potential relevance for the 
understanding of disease-induced brain plasticity. Systematic attempts are now 
undertaken, using positron emission tomography and a ligand with relative selectivity for 
activated microglia to develop generic imaging tools for a cellular in vivo neuropathology 
(Banati, 2003). 
1.1. Biology of glial cells 
Glial cells are derived from a Greek word meaning glue; although in reality glia 
do not commonly hold nerve cells together. Preferably, they surround the cell bodies, 
axons and dendrites of neurons. As far as it is known, glias are not directly involved in 
information processing but they are thought to have several other vital roles:  
• Glia cells support neurons; they separate and insulate neuronal groups and 
synapses. 
• Oligodendrocytes and Schwann cells are also type of glial cells, which 
produce myelin that is used to insulate nerve cell axons, and facilitate 
conduction of electrical signals. 
• There are some glial cells known to be scavengers, removing debris after 
injury or neuronal death.  
• Efficient signalling between neurons promotes the important 
housekeeping cores by glial cells. 
• Some classes of glial cells (radial glia) guide migrating neurons and direct 
outgrowth of axon during brain development.  
• Glial cells actively regulate the assets of the presynaptic terminals at the 
nerve-muscle synapse of vertebrates. 
• Never the less some glial cells like astrocytes play crucial roles in forming 
an impermeable lining in the brain’s capillaries and venules the blood-
brain barrier that prevents toxic substances in the blood. 
Some glial cells are known to release growth factors and help to nourish nerve 
cell. In the vertebrate nervous system, glial cells divide into two major classes: microglia 
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and macroglia. Macroglia; are broadly categorized into three types, predominantly found 
in the vertebrate nervous system: oligodendrocytes, Schwann cells and astrocytes 
(Kandel, 2000). 
Oligodendrocytes and Schwann cells are comparatively small cells that have 
relatively few processes. Functionally, these cells insulate the axon, forming the myelin 
sheath. Oligodendrocytes envelop on an average about 15 axonal internodes each. 
Schwann cells occur in the peripheral nervous system. The types of myelin produced by 
oligodendrocytes and Schwann cells differ to some degree in chemical makeup. 
Astrocytes, the most abundantly found glial cell, may play an important role in bringing 
nutrients on the surface of nerve cells in the brain and spinal cord. Thus, some astrocytes 
place end-feet on the brain’s blood vessels and cause the vessel’s endothelial cells to 
from tight junctions creating the protective blood-brain barrier. Astrocytes also help to 
maintain the proper potassium ion concentration in the extracellular space between 
neurons. They also take up neurotransmitters from synaptic zone after release and help to 
regulate synaptic activities by removing transmitters. The role of astrocytes is largely a 
supporting one (Kandel, 2000). 
 1.1.1 Origin of microglia 
For today's neuropathologist, it must be hard to believe that those microglia were 
once considered as endangered species. Yet, a few years ago, it was suggested that the 
existence of the microglia was in doubt and their name should be abandoned. Since the 
initial comprehensive description of microglia by del Rio-Hortega in 1932, the exact 
origin of microglia remains the subject of debate (Hong, 2003). What can be regarded as 
a gross scientific error by today's standards is a long and complicated history of 
microglia. Discovered independently by Nissl and Robertson, microglia cells were first 
studied in detail by del Rio-Hortega (Rio-Hortega, 1932). Rio-Hortega also deserves 
credit for establishing valuable knowledge on the role of microglia in CNS pathology. 
However, in the following years and mainly due to a lack of cell type-specific markers, 
controversy arose around microglial embryonic development and their 'nature' as well as 
their cellular 'identity' was unclear. In the mid-1980s, microglia was "rediscovered" with 
the advent of immunocytochemistry and lectin markers. Meanwhile, the esoteric debate 
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that surrounded microglia for decades had given way to research activity involving a 
broad circle of scientists. As a result, more than thousand papers have been published on 
microglia over the last few years. The biology and function of microglia are central in 
many issues in modern neuropathology. In addition, it is becoming increasingly clear that 
certain molecules and signal regulatory proteins expressed by microglia have the 
potentiality of serving as diagnostic "sensors" in day-to-day neuropathological practice 
(Graeber, 1994). 
Microglial cells are close cousins of other phagocytic cells including macrophages and 
dendritic cells. Though the origin of microglia is a matter of debate, some research 
groups still suggest that microglia derive from mesodermal precursor cells of possibly 
hematopoietic lineage that enter the brain during the embryonic and early postnatal 
phases of development (Barron, 1995; Cuadros, 1998). Other research groups shown that 
mcroglia are derived from myeloid progenitor cells (such as macrophages and dendritic 
cells) which come from the bone marrow. During embryonic development, however, they 
migrate in to the CNS to differentiate into microglia. (Streit et al, 2004). 
 1.1.2 Immune function of microglia 
Microglia, the smallest of the glial cells, can act as phagocytes, cleaning up CNS 
debris. They are representatives of the immune system in the brain and spinal cord. 
Microglia protects the brain from invading microorganisms and is thought to be similar in 
nature to macrophages in the blood system (Streit etal, 2004). 
The most characteristic feature of microglial cells is their rapid activation in 
response to even minor pathological changes in the CNS. Microglia activation is a key 
factor in the defence of the neural parenchyma against infectious diseases, inflammation, 
trauma, ischemia, brain tumours and neurodegeneration. Microglia activation occurs as a 
graded response in vivo. The transformation of microglia into potentially cytotoxic cells 
is under strict control and occurs mainly in response to neuronal or terminal degeneration, 
or both. Activated microglia cells are mainly scavenger cells but also perform various 
other functions in tissue repair and neural regeneration. They form a network of immune-
alert resident macrophages with a capacity for immune surveillance and control. 
Activated microglia can destroy invading microorganisms, remove potentially deleterious 
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debris and promote tissue repair by secreting growth factors. An understanding of 
intercellular signalling pathways for microglia proliferation and activation could form a 
rational basis for targeted intervention on glial reactions to injuries in the CNS 
(Kreutzberg, 1996). 
Microglia respond to tissue insult with a complex array of inflammatory cytokines 
and actions, these actions transcend the historical vision of phagocytosis and structural 
support that has long been enshrined in the term "reactive gliosis." Microglia are now 
recognized as the prime components of an intrinsic brain immune system (Streit, 1995), 
such they have become a focus in cellular neuroimmunology and therefore in 
neuroinflammation. This is not the inflammation of the adaptive mammalian immune 
response with its array of specialized T-cells and the made-to-order antibodies produced 
through complex gene rearrangements. This is, instead, the innate immune system, upon 
which adaptive immunity is built (Medzhitov, 2000). Chronic microglial activation is an 
important event in neurodegenerative diseases which can lead to chronic neuronal 
dysfunction, injury as well as loss and hence to disease progression. The recognition of 
microglia as the brain's intrinsic immune system and the understanding that chronic 
activation of this system leads to pathologic sequelae, has led to the modern concept of 
neuroinflammation. This vision of microglia-driven neuroinflammatory responses with 
neuropathological consequences has extended the older vision of passive glial responses 
that are inherent in the concept of "reactive gliosis"(Wolfgang, 2004). 
 1.1.3 Interaction with other brain cells 
Communication among glial populations and between glial and neuronal 
population as well as immune cells is also based on cytokines (Hanisch, 2002). 
Hematopoietic cells and the cytokines are produced and are effective in most cell type. 
Certain members have been postulated to possess neurodevelopment function; other 
modulates neurotransmitter and neurosecretion or participate in the neuroimmune-
endocrine communication (Hanisch, 2001a, Raber, 1998). 
Microglia is an integral component of the CNS (Giulian, 1995); (Streit, 2002). 
Microglia is embedded in a population of most heterogeneous cell type and carries the 
function of monitoring their well-being (Raivich, 1999, Streit, 2002). There is currently 
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enormous research progress concerning the ability of the glial cells to communicate with 
neurons and each other. As much as astrocytes are shown to act as active partners in 
neuronal information processing beyond their contribution to metabolic and homeostatic 
support as much microglia appear to collect multiple signal from both glia and neuron for 
maintaining or switching level of alert and activity (Bezzi, 2001, Polazzi, 2002, Polazzi, 
2003). Since the various region and structure of the CNS vary in the type of cells and 
neurotransmitter phenotype microglia should also be considered having regional variation 
in sensory and executive features. Age and gender difference can be demonstrated as well 
(Hanisch, 2002). 
Microglia contributes significantly to the mass of anaplastic astrocytomas 
whereas they are infrequent in low-grade examples and oligodendroglioma. Tumour-
microglial interactions in glioma are complex and still poorly understood. The fact that 
astrocytoma manage to survive and grow in the presence of activated microglia indicates 
the failure of normal defence mechanisms and suggests that microglia may contribute to 
tumour progression by favouring the survival of tumour cells and sustaining their 
proliferation and migration. Recent studies suggest that the capacity of microglia to 
secrete cytokines, upregulate costimulatory molecules and activate anti-tumour T-cells is 
insufficient to initiate a normal immune response in the environs of the tumour. It is still 
unclear whether microglial impaired response in astrocytoma is determined by the 
molecules secreted by neoplastic cells or if tumour infiltrating microglia are somehow 
defective. On the other hand, effective microglia-lymphocyte communication for antigen 
presentation and reciprocal influences are readily inducible upon microglial activation 
(Aloisi, 2001).  
 1.1.4 Microglial defence and involvement in cerebral diseases   
Signal for microglia activation needs to be translated into pattern of inducible 
function. Microglia can rapidly response or organize for response by other cells (Beattie, 
2002, Draheim, 1999, Häusler, 2002). Cellular changes are believed to be trigged within 
minutes. Microglia cells can quickly migrate to a site of injury or infection, following 
chemotactic gradient as built up by endogenous factor or factor released from the 
irritating material (Hanisch, 2004). Microglia and brain macrophages have been 
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recognized to play crucial roles in important diseases such as viral infections, 
autoimmunity and neurodegenerative disorders. HIV encephalitis, multiple sclerosis and 
Alzheimer's disease are examples where understanding the role of microglia promises to 
hold essential information concerning disease pathogenesis (Graeber, 1994). Microglias 
are thought to be highly mobile cells that play numerous important roles in protecting the 
nervous system. They are also thought to play a role in neurodegenerative disorders such 
as Alzheimer's disease, dementia, multiple sclerosis and amyotrophic lateral sclerosis. 
Microglias are responsible for producing an inflammatory reaction (Streit et al., 2004) 
and as well they are relatively under-recognized, widely distributed cell population within 
brain parenchyma constituting about 1 to 2% of all cells. They have been well known to 
neuropathologists since they harbour agents including viruses such as HIV-1, treponema 
pallidum, fungi and prions during sub-acute or chronic CNS infections. This emphasizes 
their relationship to macrophages. Parenchymatous microglias are considered to be 
resident macrophages, and contribute to inflammation within the CNS and development 
of the glial nodules present in certain viral and fungal CNS infections. Perivascular 
microglia contributes to the blood-brain barrier. Therefore, pathological abnormalities 
induced by one agent may compromise the integrity of the blood-brain barrier and permit 
entry of another pathological agent which, by it self, would not be able to pass the barrier.  
Microglia are considered to be of bone marrow origin (Streit et al., 2004) but it is still not 
known when in embryonic life these bone marrow elements enter the CNS and, therefore, 
the environment to which they are exposed including other embryonic cells and types of 
trophic factors. Their relationship to blood-borne macrophages remains unclear including 
presence and timing of activation, ability to phagocytose and phenotypic markers. It is 
unknown whether they can traverse back across the blood-brain barrier while carrying 
infected particles, genes or trophic factors.  
 Microglias are specialized cells in the brain that act as a kind of guard for the 
immune system. They may serve as “front-line defenders” or as “recruiters” of other 
immune-system agents. These cells activated early in the course of Alzheimer’s disease, 
but their function still are not well understood. It is unclear whether; 
(1) Activated microglia might be good for “eating up” beta-amyloid, a key 
suspect in Alzheimer’s;  
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(2) Activated microglia might be bad because they recruit immune system cells 
that lead to potentially harmful long-term inflammation; or 
(3) Microglia might be best “turned on” at some times and “turned off” at others.  
Through observation in regions of the brain severely affected by Alzheimer’s 
disease, certain microglias have numerous cell-surface proteins such as signal regulator 
protein-beta1 (SIRPβ1), which might be particularly sensitive to beta-amyloid. Based on 
experiments with cells, we hypothesize that SIRPβ1 is a kind of “switch” that results in 
microglia being less effective at destroying beta-amyloid and more effective at enlisting 
immune-system “fighters,” called T cells, which cause inflammation.  
1.2 Family of signal regulatory protein  
Microglial cells are considered the tissue resident macrophages of the CNS 
(Kreutzberg, 1996). They represent the major resident immunocompetent cell type. 
Currently, basic and clinical neuroscience develops large interest in microglia biology. 
This is due to an accumulation of experimental and clinical data on the impact of 
microglia in neurodegeneration (Streit, 2002a, Hanisch, 2002a, Schwartz, 2003). Various 
receptors responsible for the specific recognition of targets for phagocytosis by 
macrophages have been identified (Greenberg, 2002, Platt, 1998). The best characterized 
is the Fc receptor (FcR), which recognizes the Fc region of IgG bound to antigen, 
presented on microbial pathogens (Cox, 2001, Ravetch, 2001). The phosphorylated ITAM 
then serves as a docking site for the tyrosine kinase Syk. Downstream signaling mediated 
by phosphoinositide (PI) 3-kinase or Rho family small GTP-binding proteins eventually 
triggers phagocytosis of IgG-coated (opsonized) particles (Cox, 2001, Strzelecka, 1997, 
Caron 1998; Aderem 1999, Stephens, 2002). One of such receptor family is recognized as 
signal regulatory protein (SIRPs). The SIRP family has been studied by many groups and 
has therefore been given various names, as shown in TABLE 1. (Brown, 2006) 
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The SIRP nomenclature is the most widely used and has recently been 
summarized (van den Berg, 2005). We used SIRP-gamma rather than SIRPβ2 to 
distinguish it from SIRPβ1. SIRP-gamma does not associate with DAP12, as observed 
for SIRPβ1 (van den Berg, 2005). 
 1.2.1 Structure of SIRP family. 
SIRPs family is divided into at least three subfamily isoforms - referred to as 
SIRP-alpha (α), SIRP-beta (β) and SIRP- gamma (γ) (van den Berg, 2005). Signal 
regulatory proteins are all contain an N-terminal extracellular domain, a signal 
transmembrane domain and a C-terminal intracellular domain. Based on the structure of 
their transmembrane and /or intracellular domain and their potential role in signal 
transduction, SIRP-α has long intracellular domain that comprises two putative 
immunoreceptor tyrosine-based inhibition motif (ITIM). Studies have suggested that 
activation of SIRP-α ITIMs delivered inhibitory signal that negatively regulate cell 
responses (Kharitonenkov, 1997). In contrast, SIRPβ1 and SIRPγ have only minimal 
intracellular tails. Studies have shown that SIRPβ1, the predominant form found in 
human leukocytes, can bind to the immunoreceptor tyrosine-based activation motif 
(ITAM) containing adaptor protein DAP12 and thus deliver positive regulatory signal 
(Tomasello, 2000, Jiang, 1999). It is unclear how SIRPγ mediates signal transduction. 
Although, the intracellular domains of SIRP isoforms are well conserved, the signalling 
pathways mediated by them are strikingly different. The extracellular domains of all 
SIRPs share highly homologous amino acid sequence and a similar structure that contain 
three Ig-like loops (Yuan Liu, 2006) as shown in fig 1. 
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Figure 1 The SIRP family: structural characterisation 
The SIRP family consists of two subtypes that differ by the presence or absence of an 
intracellular domain. The SIRP a subtype possesses a long cytoplamic domain with a proline-
rich region near the C terminus and two ITIM motifs that can bind SH2 domain-containing 
phospatases. SIRPβ1 has no cytoplamsic domain but has a charged lysine residue within its 
transmembrane domain that is relevant to its association with DAP-12. Both subtypes are 
similar in their extracellular domains, which contain three Ig-like domains. Individual amino 
acid differences are evident in the single IgV-like domain when different SIRP family members 
are compared. (Cant, 2001)
 
 1.2.2 Role of signal regulatory family 
Previous studies with cells from rat, mouse, and cattle demonstrated expression of 
SIRP molecules mainly on neuronal and myeloid cells (Adams, 1998, Timms, 1998). 
This corresponds well with the strong SIRP expression observed on the surface of human 
monocytes, granulocytes, and dendritic cells. Further analyses showed that SIRP also 
expressed on the surface of bone marrow (BM) CD33+ and CD34+ myeloid progenitor 
cells, a subset of CD19+ B lymphocytes, and on early CD34+, CD117+, and CD90+ 
hematopoietic stem/progenitor cells. This suggests that SIRP is not only involved in the 
function of myeloid cells, but may also play an important role in the regulation of stem 
cell differentiation (Seiffert, 1999). The presence of 3 immunoglobulin-like loops within 
the extracellular domain of SIRPs (Kharitonenkov, 1997) suggested that this molecule 
interacts either with a soluble ligand or with a membrane molecule on other cells. Recent 
studies have shown that SIRP is indeed involved in cell-cell interactions (Kharitonenkov, 
1998) and also (Brooke, 1998) demonstrated that the interaction of cattle SIRP on 
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monocytes with an unknown molecule on CD4+ T cells is important for T-cell activation 
and proliferation, and Sano et al in 1997 showed that rat SIRP is involved in neuronal 
contacts, as well as in the outgrowth of rat neurons (Sano, 1997). 
 1.2.3 SIRPβ1 and involvement of adapter protein DAP12 
The signal regulatory proteins (SIRPs) are a family of transmembrane 
glycoproteins which belong to the immunoglobulin (Ig) superfamily and are expressed in 
hematopoietic cells including granulocytes, monocytes, dendritic cells and lymphocytes. 
SIRPβ1 one of the members of SIRP family was reported to be physically associated with 
the immunoreceptor tyrosine-based activation motif containing adapter protein DAP12. 
SIRPβ1 has shown to be involved in phagocytosis. Furthermore, gene transcripts of this 
DAP12 associated protein are down regulated in the central nervous system of the 
patients with the inflammatory Nasu-Hakola brain disease (unpublished observation, K. 
Takahashi). Nasu Hakola disease (NHD) also known as membranous lipodystrophy was 
reported by Nasu (Nasu, 1970) and Hakola (Hakola, 1972). The main symptoms of 
membranous lipodystrophy are those of a progressive presenil dementia due to sclerosing 
leukoencephalopathy with skeletal polycystic lesions (Ahn, 1996, Akai, 1977, 
Mastushita, 1981). NHD is a progressive dementia that presents accompanied by bone 
cysts and, at random, epilepsy. It is an autosomal recessive hereditary disease and its 
genetic defect is located on the 19q13.1 chromosome. The genetic mutation was 
identified at DAP12. It appears that DAP12 is expressed in the microglial activation and 
the differentiation of macrophages in the central nervous system and at the same time, in 
the osteoclasts in charge of bone remodelling (Molina-Monasterios, 2003). 
SIRPβ1 is a transmembrane protein that possesses three Ig-like domains in its 
extracellular region and a short cytoplasmic tail (Kharitonenkov, 1997). As mentioned 
earlier, SIRPβ1 has a basic amino-acid side chain in its transmembrane region that is 
essential for association of the activating adapter protein DAP12. Cytoplasmic region of 
SIRPβ1 there are only 6 amino acids and it lacks signalling motifs for association with 
phosphatases. Instead, this protein associates with DNAX activation protein 12 (DAP12, 
also known as KARAP) (Deitrich, 2000, Tomasello, 2000). 
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Figure 2. (Brown, 2006) 
DAP12 is a dimeric adapter protein that contains an immunoreceptor tyrosine-
based activation motif (ITAM) and can associate with SIRPβ1 through an amino acid 
with a basic side chain in the transmembrane region of SIRPβ1 (Tomasello, 2005, Lanier, 
2000) and transmit activating signals. The involvement of other signalling adapter 
proteins in some cell types has been suggested (Liu, 2005). Recent studies have also 
shown that SIRPβ1 is expressed as a disulphide-linked dimer (Liu, 2005), whereas SIRPα 
and SIRPγ are monomeric proteins (Brooke, 2004, Piccio, 2005). It was initially 
discovered based on its homology to another transmembrane protein, known as SHP 
substrate-1 (SHPS-1) or SIRPα (Kharitonenkov, 1997). Human SIRPβ  expressed in 
monocytes and granulocytes but not in lymphocytes (Seiffert, 2001). The protein forms a 
complex with DAP12 in human monocytes or in transfected nonhematopoietic cells 
(Deitrich, 2000, Tomasello, 2000). DAP12 is a transmembrane protein, which was 
originally identified based on association with the inhibitory receptors of natural killer 
cells (Lanier, 1998, Wu, 2000). Its intracellular region contains a single ITAM motif 
which binds Syk or the tyrosine kinase ZAP-70. The association between SIRPβ1 and 
DAP12 is thought to be mediated by an ionic interaction between single amino acids of 
opposite charge (lysine of SIRPβ1 and aspartic acid of DAP12) within the 
transmembrane regions (Deitrich, 2000, Tomasello, 2000, Cant, 2001). Ligation of 
SIRPβ1 resulted in the tyrosine phosphorylation of DAP12 and the subsequent 
recruitment of Syk to the SIRPβ1-DAP12 complex in RBL-2H3 cell transfectants 
(Tomasello, 2000). SIRPβ1 is therefore implicated as a positive regulator of 
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hematopoietic cells. To obtain the optimal type and strength of the immune response that 
is required to eliminating pathogen while minimizing the side effects, the response is 
regulated through a balance of activating and inhibitory signals that are delivered by 
receptors on the surface of the cell immune system. One such group of cell-surface 
receptors is the signal regulatory protein (SIRP) family. In this thesis, we emphasize the 
molecular aspect of the interaction between the SIRPβ1 and their adapter protein 
molecule DAP12 and show how they might be involved in immune-cell regulation. 
 
The physical association between SIRPβ1 and KARAP/DAP-12 results in the 
functional coupling of SIRPβ1 engagement to the recruitment of the protein tyrosine 
kinase Syk and to serotonin release in rat basophilic leukemia (RBL) cell transfectants 
(Tomasello, 2000). Signalling pathway activated by SIRPβ1 promotes phagocytosis in 
macrophages (Fig. 3). Engagement of SIRPβ1 (Tomasello, 2000) by its putative ligand 
induces the tyrosine 
phosphorylation of DAP12 and the 
subsequent recruitment of Syk to 
DAP12 and its tyrosine 
phosphorylation. Activated Syk 
then mediates the tyrosine 
phosphorylation of SLP-76, which 
forms a multiprotein complex that 
triggers activation of the MEK-
MAPK-MLCK cascade.  
 
 
 
Figure 3. Proposed model for the signaling pathway underlies the 
promotion of phagocytosis by SIRPβ1 in macrophages.  
 
MLC phosphorylation by MLCK increases myosin ATPase activity and elicits the 
reorganization of the actin cytoskeleton that underlies promotion of the phagocytic 
response (Hayash, 2004) as shown in figure 3. 
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Role of SIRPβ1 was partially investigated in macrophage function and the effect 
of SIRPβ1 engagement was examined by specific monoclonal antibodies (mAbs) on 
phagocytosis as well as on intracellular signalling (Hayash, 2004). A physiological ligand 
for SIRPβ1 remains to be identified. The ligand of SIRPβ1 might be a soluble protein, 
such as IgG or complement, which binds to a phagocytic target. Alternatively, it might be 
a microbial component such as bacterial lipopolysaccharide or peptidoglycan, both of 
which recognized by Toll-like receptors on macrophages or dendritic cells (Fujioka, 
1996). We investigated the functional role of SIRPβ1 in microglia by analyzing the effect 
of SIRPβ1 engagement on phagocytosis, inflammatory responses as well as on 
intracellular signalling in microglia with specific monoclonal antibodies (mAbs). 
1.3 Lentiviral vectors 
With the human genome sequence in hand and rapid progress in its annotation, 
gene transfer will become a major tool in functional genomics, animal transgenesis, and 
gene therapy. The need for effective gene transfer systems is obvious, and number of 
gene transfer systems are being developed. Among these are lentiviral vectors, which 
have certain advantages over other vector systems. Lentiviral vectors integrate into the 
host genome. This is a useful property where a stable and long-term expression of the 
transgene is required and it obviates the need for repeated vector administration.  This 
approach may be useful for directing gene therapy treatment to specific tissues and 
organs. In addition, gene delivery to the whole brain to treat global neuronal degenerative 
disorders could best be accomplished by targeting the viral vector for transport across the 
blood brain barrier and thus widespread distribution over the whole brain. 
 1.3.1 Introduction to lentivirus 
Lentiviral vectors are a type of retrovirus that can infect both dividing and non-
dividing cells because their preintegration complex (virus “shell”) can get through the 
intact membrane of the nucleus of the target cell.  Lentiviruses can be used to provide 
highly effective gene therapy as they can change the expression of their target cell's gene 
for up to six months.  They can be used for non-dividing or terminally differentiated cells 
such as neurons, macrophages, hematopoietic stem cells, retinal photoreceptors, and 
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muscle and liver cells, cell types for which previous gene therapy methods could not be 
used.  HIV is a very effective lentiviral vector because it has evolved to infect and 
express its genes in human helper T cells and macrophages.  The only cells lentiviruses 
cannot gain access to are quiescent cells (in the G0 state) because this blocks the reverse 
transcription step (Amado and Chen, 1999). Lentiviral vectors, which are derived from 
retroviral vector, are considered the ideal gene delivery system. Potential of lentiviral 
vector was first revealed in 1996 through the demonstration that they could transduce 
neurons in vivo. Their ability to integrate into the genome of target cells allows for long 
term gene expression and they do not induce an immunological response and they have a 
large cloning capacity (up to 10kb). However, retroviral vectors have a major drawback 
in that they fail to infect nonmitotic cells (Lewis, 1994, Roe, 1993).  
 1.3.2 Genomic structure of lentiviruses   
To obtain a lentiviral gene vector, a reporter gene or therapeutic gene is cloned 
into a vector sequence that is flanked by LTRs and the Psi-sequence of HIV.  The LTRs 
are necessary to integrate the therapeutic gene into the genome of the target cell, just as 
the LTRs in HIV integrate the dsDNA copy of the virus into its host chromosome.  The 
Psi-sequence acts as a signal sequence and is necessary for packaging RNA with the 
reporter or therapeutic gene in virions. Viral proteins, which make virus shells, provided 
in the packaging cell line, but are not in context of the LTRs and Psi-sequences and so are 
not packaged into virions.  Thus, virus particles are produced that are replication deficient 
and are designed to be unable to continue to infect their host after they deliver their 
therapeutic content (Schmidt 2000). The life cycle of the lentivirus is common to all 
members of the Retroviridae family and can be described by the following steps 
(schematically represented in figure 4): 
1- Attachment and entry: the interaction between the virus and the target cell occurs via 
specific receptors. Once bound to the surface, the viral and cellular membranes undergo 
fusion. After this fusion step, the virion nucleoprotein is delivered to the cytoplasm where 
reverse transcription begins.  
2- Reverse transcription: synthesis of double stranded DNA from a RNA template carried 
out by the reverse transcriptase enzyme using cellular tRNA as a primer.  
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3- Integration: once the DNA synthesized, the viral integrase catalyzes its integration into 
the host genome and allows the provirus to become a permanent genomic element in the 
host. 
4-Transcription and viral protein synthesis: the first transcription products from the virus 
code for the REV TAT and NEF. At a later stage, un-spliced and single spliced RNA 
species are produced. 
5-Virion assembly and release: viral genome and structural proteins are packed into the 
viral particles and released at the plasma membrane.  
                       
 
 
Figure 4.  Schematic representation of a retrovirus life cycle, which can be described in 5 steps 
from attachment of the virus till the new virion assembly and release.
Lentiviruses comprise one of three subfamilies of retroviruses, which also include 
the oncoviruses (RNA tumour viruses) and spuma (or foamy) viruses. Members of all 
three subfamilies are able to infect humans and are associated with a spectrum of 
pathogenic potential, from no disease (as in the case of foamy viruses) to cancer (human 
T leukemia viruses, HTLV), immune deficiency (human immunodeficiency virus, HIV), 
and neurological disorders (HTLV and HIV). The first lentivirus was isolated in 1904 
from a horse with haemolytic anemia and was named equine infectious anemia virus 
(EIAV) (Vallee, 1904). Since then, related viruses have been isolated from other ungulate 
species (e.g. - visna-maedi virus from sheep; caprine arthritis/encephalitis virus, CAEV, 
from goats; bovine immunodeficiency virus from cows, cats feline immunodeficiency 
virus, FIV nonhuman primates simian immunodeficiency virus, SIV), and humans 
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(Clements, 1992). Lentiviruses are generally associated with chronic diseases of the 
immune system and the central nervous system.  
All retroviral derived lentiviruses contain minimally three genes, gag, pol, and 
env, which encode the structural proteins as well as the enzymes (reverse transcriptase, 
RNase H, integrase, and protease) required for virus replication. However, lentiviruses 
contain additional genes that are essential for or contributory to efficient virus replication 
and persistence. The prototype lentivirus, HIV-1, encodes six additional genes (tat, rev, 
vif, vpu, vpr, and nef) (figure 5). 
 Figure5. The non-primate 
lentiviruses contain fewer of these 
extra genes, but all contain the tat 
and rev genes, which are 
responsible for transcriptional and 
posttranscriptional activation of 
viral gene expression respectively 
(http://biology.kenyon.edu)
 
 
 
 
 
 
 
 
  1.3.3 Lentiviral vectors for gene therapy  
The discovery that human immunodeficiency virus-type 1 (HIV-1) can infect both 
mitotic and non-mitotic cells (Bukrinsky, 1999, Bukrinsky, 1992) has led to the 
development of a new class of retroviral vector to be used for gene therapy. These vectors 
are termed lentiviral vectors, “lenti” being the Latin term for slow, referring to a slow and 
persistent rate of infection. It is the ability of this newly developed lentiviral system to 
allow infection of quiescent cells, which has brought a new hope to the field of gene 
therapy. While a number of lentiviruses have been described, the best understood is HIV-
1 and thus most experimental vectors are based on this system. The first lentiviral vectors 
to use experimentally were not intended for use in gene delivery but for the study of HIV-
1 pathogenicity. These vectors normally contained the entire viral genome with the 
exception of the env gene. A reporter gene was expressed in place of env and the 
envelope protein was then expressed by another construct (Page, 1990; Landau, 1991). 
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The development of replication 
incompetent lentiviral vectors 
designed for the purpose of gene 
delivery began with the realization that 
lentiviral vectors may have some 
benefit over onco-retroviral vectors. 
The first generation of lentiviral 
vectors separated structural genes 
between two constructs. All cis-acting 
sequences were contained within a 
third construct expressing the gene of 
interest (Parolin, 1994). While this system worked, it gave low viral titers and was 
limited to the transduction of the natural target cells of HIV-1. Later vectors expressed 
structural elements on one construct under the control of the cytomegalovirus (CMV) 
immediate early promoter. Now days it is widely used by many research groups to 
analyse several mechanisms in central and peripheral nervous system.  
 
 
Figure 6 pLenti6/V5 D-topo plasmid map 
From Web-site (www.invitrogen.com) 
 The second vector was used to express the envelope protein, normally the 
vesicular stomatitis virus G-protein (VSV-G). The VSV-G protein confers pantropic 
activity on viral particles and allows for greater stability (Bartz, 1997; Burns, 1993). The 
third generation construct contained all required cis-acting sequences, e.g. the 5’ and 3’ 
LTRs and ψ, and the gene of interest under control of the appropriate promoter (Naldini, 
1996). Such constructs made expression dependent on the presence of trans-acting 
proteins expressed from the first construct. While being functional, such vectors raised 
questions about safety, as homologous regions shared between the different constructs 
anticipated recombination events, which could give rise to replication competent viral 
particles (Hu, 1990). The second generation of lentiviral vectors tackled this problem by 
removing large amounts of the viral genome later discovered unnecessary for gene 
delivery. The use of the third generation of lentiviral gene delivery system is the 
replacement of the U3 region of the 5’ LTR with a constitutively active promoter has 
allowed the removal of Tat from the system (Kim, 1998). In addition, it was found that 
Rev could be contributed from a separate vector (Dull, 1998). Thus, the vector expressing 
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structural and regulatory proteins no longer contains sequences for Tat and Rev. This 
third generation system is self-inactivating (SIN) to prevent the possible unwanted 
expression of genes proximal to the site of integration. Such transcriptional read through 
is due to transcriptional activity of the 5’LTR promoter as well as deficient cleavage and 
polyadenylation of vector transcripts within the 3’LTR (Swain, 1992). During reverse 
transcription, the 5’LTR of the resulting viral DNA derived from the 3’LTR of the viral 
RNA. The SIN system was accomplished by deleting the U3 region of the 3’ LTR 
(Zufferey, 1998). The modified 3’ LTR allows viral packaging but self inactivates the 5’ 
LTR for biosafety purposes (Miyoshi, 1998). The element also contains a 
polyadenylation signal for efficient transcription termination and polyadenylation of 
mRNA in transduced cells (Iwakuma, 1999; Swain, 1989). An added advantage of this 
modification is that the elimination of transcription from the viral LTR allows the 
possibility for tissue specific expression upon the use of the appropriate promoter. 
 1.3.4 Silencing-lentivirus vector 
In the RNAi field, it was discovered that plasmid-based RNAi could substitute for 
synthetic siRNAs, thus permitting the stable silencing of gene expression 
(Brummelkamp, 2002). In such systems, an RNA polymerase III promoter used to 
transcribe a short stretch of inverted DNA sequence, which results in the production of a 
short hairpin RNA (shRNA) that processed by Dicer to generate siRNAs. These vectors 
have been widely used to inhibit gene expression in mammalian cell systems (Ventura, 
2004). Although the molecular mechanism of siRNA is not completely understood, it is 
generally believed that siRNA induces the degradation of target mRNA in a sequence-
specific manner, leading to posttranscriptional silencing of gene expression. As such, 
siRNA could potentially be used both as a research tool and as a therapeutic approach.  It 
is clear that siRNA-based gene silencing is still an evolving technology. It remains an 
open question whether the in vivo application of siRNA in mammals will revolutionize 
biomedical research and therapeutics or whether it is just one more tool with narrow 
utility. Indeed, clinical trials using siRNA to treat viral infection and other diseases are 
appearing on the horizon, the outcome of which will certainly have a tremendous impact 
on the fate of the entire siRNA field (Check, 2004). RNA interference (RNAi) has 
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emerged as a powerful tool to silence gene expression, and has rapidly transformed gene 
function studies across phyla. RNAi operates through an evolutionarily conserved 
pathway that is initiated by double-stranded RNA (McManus, 2002; Dykxhoorn, 2003). 
The ability of dsRNA to affect gene expression was already well known in mammals; 
here, a series of interferon-inducible pathways respond to dsRNA by inhibiting 
translation through the action of a dsRNA-activated protein kinase (DAI or PKR) 
(Williams, 1999). The key difference between this response and RNAi was their 
respective specificity: the PKR response inhibited gene expression globally, whereas 
RNAi had a specific effect on gene expression. A more specific dsRNA response in 
mammalian cells had also been proposed to operate through the localized activation of a 
ribonuclease that responds indirectly to dsRNA (Stark, 1998). The latter pathway might 
have provided a plausible explanation for RNAi, as it was clear that the targeted mRNA 
destroyed in response to dsRNA. However, a series of startling observations made it clear 
that RNAi was mechanistically distinct from any previously known dsRNA response. 
One of the first indications that RNAi was a novel biological phenomenon was the 
potency of its effect. The study described in this thesis employs the use of the third 
generation silencing lentiviral gene delivery system, which well known as LentiLox 3.7. 
This is a lentiviral vector designed for inducing RNA interference in a wide range of cell 
types, tissues and organisms. Rubinson et al (2003) have shown this vector to infect and 
efficiently silence proteins in hematopoietic stem cells and their progeny, and have used 
infected embryonic stem cells and single cell embryos to create transgenic animals 
(Douglas, 2003). Current approaches to study gene function such as generating knockout 
mice are time-consuming and expensive and cannot be applied to human tissues. RNAi 
has emerged as a rapid and efficient means to manipulate gene function in mammalian 
cells (McManus, 2002). 
Retroviral vectors are efficient, stable gene delivery tools in mammalian cells 
(Lois, 2001; Scherr, 2002), and recent studies suggest that they can stably express 
shRNAs in transformed and primary cells (Brummelkamp, 2002). A lentivirus-based 
vector (pLL3.7) is developed that expresses RNAi-inducing shRNAs under the control of 
the U6 promoter Fig.7 (Tuschl, 2002).  
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Figure 7.  Schematic diagram of pll3.7 silencing vector. 
This pll3.7 vector was engineered to co-express enhanced green fluorescent 
protein (EGFP) as a reporter gene, permitting infected cells to be tracked by flow 
cytometry. Lentiviruses have two key advantages over other gene delivery systems. First, 
they can infect non-cycling and post-mitotic cells (Naldini, 1998; Naldini, 1996). Second, 
transgenes expressed from lentiviruses are not silenced during development and can be 
used to generate transgenic animals through infection of embryonic stem (ES) cells or 
embryos (Pfeifer, 2002; Lois, 2002). In addition, Takahashi et al. demonstrated in 2005 
that TREM2 knockdown microglia with the help of lentivirus-based background vector 
(pLL3.7) showed reduced phagocytosis. Thus, Deficiency of TREM2 results in impaired 
uptake of apoptotic neurons and increased production of inflammatory mediators 
(Takahashi, 2005). 
RNA interference (RNAi) is a mechanism in molecular biology where the 
presence of certain fragments of double-stranded RNA (dsRNA) interferes with the 
expression of a particular gene that shares a homologous sequence with the dsRNA. 
RNAi is distinct from other gene silencing phenomena in that silencing can spread from 
cell to cell and generate heritable phenotypes in first generation progeny when used in 
Caenorhabditis elegans (Guo, 1995). RNAi appears to be a highly potent and specific 
process which is actively carried out by special mechanisms in the cell, known as the 
RNA interference machinery. While not all details of this mechanism are known, it 
appears that the machinery once it finds a double-stranded RNA molecule, gets processed 
into 20-25 nucleotide (nt) small interfering RNAs (siRNAs) by an RNase III-like enzyme 
called Dicer (initiation step), Then the siRNAs assemble into endoribonuclease-
containing complexes known as RNA-induced silencing complexes (RISCs), unwinding 
in the process which separates into two strands. The siRNA strands subsequently guide 
the RISCs to complementary RNA molecules, where they cleave and destroy the cognate 
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RNA (effector step). dsRNAs direct the creation of small interfering RNAs (siRNAs) 
which target RNA-degrading enzymes (RNAses) to destroy transcripts complementary to 
the siRNAs. Cleavage of cognate RNA takes place near the middle of the region bound 
by the siRNA strand.  
 
Another 
way to 
present 
 
 
 
http://www.ambion.com/techlib/append/RNAi_mechanism.htmhttp://www.panomics.com/SR1000.cfm 
Figure 8. Scechmetic presentation of silencing mechanism. 
One of the great mysteries surrounding RNAi is how a cell can respond to 
virtually any incoming dsRNA by efficiently and specifically silencing genes that are 
homologous to it. Since the seminal discovery of small RNA species, progress in both 
genetic and biochemical dissection of the silencing process have produced a basic 
understanding of the interference mechanism (Hammond, 2001). 
  1.3.5 Production of lentivirus  
If a more concentrated lentiviral vector suspension is required, the vector 
preparation needs to be concentrated. Titers of viruses in general and lentivectors in 
particular are critically capable of achieving every step from cell binding to expression of 
the transgene depending on both vector and cell characteristics. Lentiviral vector contains 
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CMV promoter and a flurorescent protein gene as a reporter, under the control of a 
promoter that is active in most primary cells (Salmon, 2000). For several years now, 
293FT cells have been using as a target. These cells are stable, easy to grow and 100% 
susceptible to transduction by VSV-G pseudotyped LVs. These are also now commonly 
used by many laboratories, which thus help comparing titers between them. The 
production of functional lentiviral particles performed by co-transfection of a packaging 
cell line with four different vectors as described. As Gag and Pol proteins are not 
assembled accordingly in murine cells, this procedure is performed in a human cell line 
(Swain, 1989) , the cell line of choice normally being based on 293FT cells, a human 
embryonic kidney cell line. For reasons still unknown, many other common laboratory 
cell lines, e.g.HeLa, successfully transfected and produce large amounts of viral protein 
but secrete only few viral particles (Haselhorst, 1998). The cell line used in this study is 
293FT. The 293F cell line is a fast growing variant of 293 cells. 293FT cells are a variant 
of 293F stably expressing the SV40 large T antigen allowing for the replication of 
plasmids containing the SV40 origin of replication, which is present on the transfer 
vector used. Viral particles are secreted into the culture medium from which they are 
collected. Transduction of hematopoietic cells cultured in serum free medium is 
estimated to require anywhere between 107 and 108 transducing units18, (McTaggart, 
2000). The pseudotyping of viral particles with the VSV-G protein allows for great 
stability compared to those with viral glycoproteins. 
VSV-G pseudotyped particles may be stored at 4oC for 2-3 days, can tolerate a 
freeze and thaw cycle and may be concentrated 100-fold by ultracentrifugation, all 
without a significant loss in viral titer (Bartz, 1997). The only disadvantage of using 
VSV-G pseudotyped virus is its inactivation upon contact with human serum, limiting its 
experimental use (DePolo, 2000). Secretion of viral particles exists maximal 24hr 
following transfection and decreases two-fold in the second 24 hours period. Low viral 
titers may be dealt with by altering culture conditions, e.g. decreasing the temperature to 
32oC as well as using low serum concentration (2%).  
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  1.3.6 Biosafety of lentivirus 
The general idea is to avoid contamination with the recombinant virus, which 
spreads through liquid or aerosol. Therefore, all the work should be contained within the 
same room. According to the decision of the Institutional Biological Committee, which 
was approved by the Institutional Safety Committee, lentivirus work is done locally, 
within the facilities of each department and is under the responsibility of the principle 
investigator. The development of the third generation lentiviral gene delivery system has 
addressed many problems of biosafety regarding the use of lentiviral vectors in the 
laboratory. These lentiviruses are pseudo-coated with VSV-G and are capable of 
infecting human cells, and thus present important biosafety issues (Douglas, 2003). The 
separation of cis and trans acting regions of the viral genome onto separate vectors has 
enabled the use of this system in scientific and clinical research. Progress in the safety 
level of its use has been achieved by decreasing the level of homogeneity between these 
vectors. However, the presence of some sequences is required on more than one vector, 
e.g. approximately 300bp of gag is required on both the packaging and transfer vectors, 
thus the possibility of recombination, while very small, must still be considered. 
Although, if such an event was to occur, infected cells could not express viral proteins 
due the self-inactivating property of the system (SIN), and transport of transcripts to the 
cytoplasm could not occur in the absence of Rev, which is delivered to packaging cells on 
its own expression vector. Another concern in clinical research is the possibility of 
recombination events between engineered virus and natural virus in patients already 
infected with HIV-1. Studies suggest that if such an event were to occur, the possibility 
of recombination between the genome of both viruses is quite likely, resulting in the 
emergence of a new viral species (Jetzt, 2000). The development of SIN lentiviral vectors 
has decreased the risk of aberrant expression of genes endogenous to the transduced cells, 
a matter of major concern in clinical gene therapy trials (Marshall, 2003). Debyer 
described how the field has engineered lentivectors with increasing biosafety both for the 
lab worker and for the patient. The risk associated with state-of-the-art lentivectors is 
therefore minimal, although a psychological barrier to use these vectors in the clinic may 
still have to be overcome. Due to their increased performance, care should be taken to 
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avoid accidental transduction of the lab worker with potential hazardous genes. The 
precautions that have to be taken described in detail (Debyser, 2003). 
1.4 EAE and APP: Autoimmune and transgenic animal 
model for function analysis of SIRPβ1 
  1.4.1 Experimental Autoimmune Encephalomyelitis (EAE)  
Animals immunized with components of CNS myelin develop an autoimmune 
demyelinating disease of the CNS called experimental autoimmune encephalomyelitis 
(EAE) (Whitehouse, 1969; Alvord, 1984; Zamvil, 1990). This disease is the result of a 
CD4C T cell–mediated immune response directed at specific proteins within the CNS, 
and it serves as a model of the human disease multiple sclerosis (MS). 
In the case of EAE, progression of disease may be attributed either to sustained 
autoreactivity directed against an immunodominant priming determinant or to acquired 
autoreactivity directed against determinants not involved in the initiation of disease. This 
acquisition of neo-autoreactivity, commonly referred to as epitope spreading, presumably 
results from endogenous priming with new self-antigens generated from damaged tissue 
over the course of disease (Lehmann, 1992; McRae, 1995; Yu, 1996; Vanderlugt, 1996). 
 1.4.2 Molecular pathogenesis of experimental autoimmune 
encephalomyelitis (EAE)  
EAE is an acute or chronic-relapsing, acquired, inflammatory and demyelinating 
autoimmune disease. The animals are injected with the whole or parts of various proteins 
that make up myelin, the insulating sheath that surrounds neurons. These proteins induce 
an autoimmune response in the animals - that is the animal's immune system mounts an 
attack on its own myelin because of exposure to the injection. The animals develop a 
disease process that closely resembles MS in humans. Several proteins or parts of 
proteins (antigens) are used to induce EAE including Myelin Basic Protein (MBP), 
Proteolipid Protein (PLP), and Myelin Oligodendrocyte Glycoprotein (MOG).  
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Advantages of EAE: 
• EAE is an animal disease; hence it enables researchers (especially 
immunologists) to study demyelination (the process underlying the symptoms of 
MS) in ways that would not be morally acceptable in studies of MS in humans.  
• It allows researchers to test potential treatments for MS for their efficacy 
and safety without putting the lives of people at risk.  
• It allows researchers to experiment with different ways of inducing EAE 
to attempt to find potential causes of MS.  
• Because the generations times of most of the EAE species are short and 
because they breed very fast, large populations of such animals can be turned over 
in short periods.  
Disadvantages using EAE:  
• EAE is not a multiple sclerosis and a number of significant assumptions 
are made when proposing EAE as an animal model of MS. 
• It is undeniable that the animals involved suffer considerably - at the very 
least they are given the animal equivalent of MS - and questions about the ethics 
of EAE are inescapable.  
Multiple sclerosis (MS) is the most common chronic disease of the CNS. "Self-
reactive" T cell, responding to the myelin components of the isolating sheath of the nerve 
cells, has been implicated in the development of MS. Even though research into MS has 
been carried out a number of years, the cause of this demyelinating disease is still not 
known. The EAE model is worldwide used as the only animal model of human MS. 
There is a strong correlation between "self-reactive" (myelin protein specific) T cells and 
disease induction in the EAE model of MS. To induce EAE, mice are immunized with 
myelin protein or peptides and monitored daily for disease development. This protocol 
induces a strong T cell response and chronic disease in C57Bl/6 mice 12-17 days after 
immunization.  
  1.4.3 Alzheimer’s disease and its pathological substrate 
Alzheimer’s disease (AD) is the most common cause of dementia. It usually 
occurs in elderly patients and starts gradually with early signs being forgetfulness, 
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particularly in remembering recent events and the names of people and things. There may 
be some other cognitive difficulties early on but nothing overly alarming. Emil Kraepelin 
first identified the symptoms of the disease as a distinct nosologic entity, and Alois 
Alzheimer (1906) first observed its characteristic neuropathology. In this sense, the 
disease was co-discovered by Kraepelin and Alzheimer, who worked in Kraepelin's 
laboratory. Because of the overwhelming importance Kraepelin attached to finding the 
neuropathological basis of psychiatric disorders, he made the generous decision that the 
disease would bear Alzheimer's name (Weber, 1997). Alzheimer himself described the 
characteristic light microscopic lesions-neurofibrillary tangles and amyloid-bearing senile 
plaques-in the limbic and cerebral cortices by using the Bielschowsky’s method of silver 
impregnation. The neurofibrillary tangles were eventually shown by electron microscopy 
to be composed of nonmembrane-bound bundles of paired, helically-wound -10-nm 
filaments (PHF) in the perinuclear cytoplasm selected neurons (Kidd, 1963; Terry, 1963). 
The senile or neuritic plaque is a complex, multicellular lesion, the temporal genesis of 
which is only imperfectly understood. So-called "classical" neuritic plaques consist of a 
compacted spherical deposit of extracellular, ~8-nm amyloid filaments surrounded by 
variable numbers of dilated (dystrophic) neuritis, both axonal terminals and dendrites. 
Many such classical plaques contain apparently activated microglial cells intimately 
surrounding the amyloid core (Wisniewski, 1989). 
  1.4.4 Molecular pathology of amyloid precursor protein 
AD is a debilitating neurodegenerative condition characterized by the loss of 
cognitive skills and severe behavioural changes (dementia). The principle protein 
implicated in the development of Alzheimer's disease is the amyloid precursor protein 
(APP). Indeed, a small subset of patients exhibiting familial AD exhibit APP mutations; 
this was the first genetic link to AD identified. Cleavage of APP by proteases known as 
secretases gives rise to a group of peptide fragments known as Amyloid β (Aβ). Aβ, 
which forms dense extracellular aggregates called amyloid plaques, has been 
demonstrated to induce neuronal death, which may ultimately lead to disease. The 
principle protein implicated in Alzheimer’s disease is the transmembrane APP. Multiple 
APP isoforms, generated by alternative splicing have been described with a 770 amino 
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acid isoform being the largest and a 695 amino acid isoform being most prevalent in 
neuronal cells. Aβ is produced by sequential cleavage of APP by proteases called 
secretases. Proteolysis of APP by β-secretase, which cleaves APP695 after Met-596, 
produces a large soluble n-terminal fragment (sAPPβ) and a small membrane-bound c-
terminal fragment (C99). The C99 fragment is further processed by γ-secretase cleavage 
within the trans-membrane region at Val-636, Ala-638 or Thr-639 to produce the three 
Aβ isoforms of 40, 42 or 43 amino acids, designated x-40, x-42 or x-43. The Aβ isoforms 
can induce neuronal apoptosis and aggregate into amyloid plaques. Progression of 
Alzheimer’s disease is associated with increased levels of the x-42 and x-43 Aβ peptides 
(Buxbaum, 2004). 
http://www.upstate.com/features/app_lp.asp  
 
However, the expression of multiple βAPP isoforms in astrocytes (Siman, 1989; 
Haass, 1991) and the observation of apparent Aβ fibrils inside microglial cells (Wegial, 
1990) have also led to hypotheses that either or both of these cells could contribute to the 
Aβ deposits. In the model of Alzheimer’s disease, (Selkoe 1994) has reviewed some very 
considerable points to new therapeutic strategies aimed at one or more crucial steps in its 
molecular progression. First, one could partially inhibit the proteases that liberate Aβ 
from its precursor. Second, one could decrease the production and release of Aβ by a 
variety of means other than protease inhibition, for example by pharmacologically 
diverting some βAPP molecules from an amyloidogenic to a nonamyloidogenic-
processing pathway. Third, one could retard the apparent maturation of extracellular Aβ 
deposits into neuritic plaques, perhaps by interfering with the fibrillogenesis that seems to 
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accompany this change. Fourth, one could interfere with the activities of microglial cells 
that contribute to the chronic inflammatory process around the neuritic plaques. This last 
point is one of our great interests in our hypothetical study for functional understanding 
of signal regulatory protein-beta1. Fifth, one could attempt to block the molecules on the 
surface of neurons or their intracellular effectors that mediate the apparent neurotoxic 
effects of Aβ and the proteins intimately associated with it. None of these 
pharmacological objectives will be easy to reach. However, the strength of accumulating 
data emerging from laboratories worldwide suggests that these are rational therapeutic 
targets which offer the best hope of slowing or arresting the progression of the 
fundamental disease process early in its tragic course (Selkoe, 1994). 
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2. Aims of the study 
Nasu-Hakola disease known as a membranous lipodystrophy (polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy-PLOSL) is an 
autosomal recessive hereditary neurodegenerative disease where genetic mutation was 
identified in DAP12. DAP12 is a 12 kDa transmembrane protein recently recognized as a key 
signal transduction receptor element in immune cells. We have found that activation signals 
initiated through DAP12 predicted to play strategic roles in triggering microglial cells. The 
cytoplasmic domain of SIRPβ1 was reported to physically associate with the ITAM 
activation motif containing adapter protein DAP12.  
Microglia constitute as many as 12% of the cells in the CNS and it seems that DAP12 
is expressed in the microglial activation and the differentiation of macrophages in the CNS. 
The study of particular neurodegenerative disease where DAP12 is dominantly express along 
with its associated receptors SIRPβ1 could give us a therapeutic outline for understanding of 
the molecular mechanism for neurodegenerative research. It would be an advantage to 
understand whether SIRPβ1 could be involved in such diseases and if yes, then what the 
functional characteristics are. Could SIRPβ1 play any crucial role in Alzheimer’s diseases 
and multiple sclerosis? In order to answer these questions we addressed to determine the 
functional assignment of SIRPβ1 in microglia. 
 
Therefore, we focused on the following tasks: 
 
1. It was prim importance to confirm expression of SIRPβ1 gene in microglial 
cells. 
2. We tried to understand whether SIRPβ1 is involved in up or down-regulation 
of important microglial cytokines. 
3. Whether stimulation of cytokine or chemokine such as interferon-gamma or 
beta does up or down-regulate SIRPβ1 and DAP12 levels in microglia.  
4. Could silencing of SIRPβ1 in microglia shows any functional imbalances in 
CNS?  
5.  Does SIRPβ1 involved in some autoimmune or Alzheimer’s like diseases?   
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3. Materials and Methods 
3.1. Materials 
 3.1.1 Buffers and solutions 
 (10X) 0.125M Phosphate-Buffered Saline (PBS), pH 7.3 
Components Concentration Company 
NaH2PO4.H2O 
Na2HPO4.7H2O 
NaCl 
ddH2O 
0.007M 
0.034M 
0.6M 
up to1 litter 
Roth, Germany 
Roth, Germany 
Roth, Germany 
Roth, Germany 
 4% paraformaldehyde (PFA), pH 7.3 
Components Amount Company 
PFA 
NaOH 
PBS(10X) 
ddH2O 
20g 
30ml 
50ml 
up to 1 litter 
Sigma, Germany 
Roth, Germany 
 
Roth, Germany 
 Lysis buffer for erythrocytes 
Components Concentration Company 
NH4Cl 
KHCO3 
EDTA 
ddH2O 
0.156M 
0.01M 
5x10-6M 
 
Roth, Germany 
Roth, Germany 
Roth, Germany 
Roth, Germany 
 (10X) TBE Buffer  
Components Concentration Company 
Tris-Base 
Boric Acid 
EDTA 
ddH2O 
1.78M 
1.78M 
0.04M 
 to 2 litters 
Roth, Germany 
Sigma, Germany 
Roth, Germany 
Roth, Germany 
 (6X) Loading buffer 
Components Concentration Company 
EDTA 
Sucrose 
Bromphenol Blue 
Xylene Cyanole 
Ficol-400 
0,5M 
60% 
0,04% 
0,04% 
2% 
Roth, Germany 
Fluke Biochemika, Germany 
Sigma, Germany 
Sigma, Germany 
Bio-Rad, Germany 
• 1% Agarose gel  
Components Amount Company 
Agarose 
Etidium Bromide or 
Gel Star (when gel extraction) 
 
0.5g 
1.25µl 
4µl 
 
SeaKem,Cambrex, USA 
Roth, Germany 
BioWhittaker Molecular 
Applications, USA 
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TBE (1X) 50ml  
• PCR reaction mix (50 µl sample) 
Components Amount Company 
dNTP mix (10mM) 
Taq polymerase(100U/20µl) 
Forward primer (10pmol/µl) 
Reverse primer (10pmol/µl) 
Buffer (10X) 
dd H2O 
1µl 
0.5µl 
3µl 
3µl 
5µl 
37.5µl 
Amersham Bioscience, USA 
Roche, Germany 
MWG, Germany 
MWG, Germany 
Roche, Germany 
Roth, Germany 
• Reverse transcription (RT) mix (20 µl sample) 
Components Amount Company 
Total RNA 
Hexanucleotide Mix (10X) 
dNTP mix (10 mM) 
DTT mix (0.1M) 
5XRT 1st Strand Buffer  
RT enzyme (200U/ml) 
dd H2O 
5µg 
1µL 
1µL 
2µL 
4µL 
1µL 
up to 20µl 
 
Roche, Germany 
Amersham Bioscience, USA 
Invitrogen, Germany 
Invitrogen, Germany 
Invitrogen, Germany 
Roth, Germany 
• Real time RT-PCR (25 µl sample) 
Components Amount Company 
SYBR Green Master Mix(2x) 
cDNA 
forward and reverse primer pair 
mix (10 pmol/µl) 
ddH2O 
12.5µl 
1µl 
 
1µl 
10.5µl 
Applied Biosystems, UK 
 
 
MWG, Germany 
Roth, Germany 
• Digestion reaction mix (20 µl sample) 
Components Concentration Company 
Enzyme 1 (10U/µl) 
Enzyme 2 (10U/µl) 
Buffer (10X) 
insert/plasmid 
ddH2O 
0.5µl 
0.5µl 
2µl 
up to1µg 
up to 20µl 
Roche, Germany 
Roche, Germany 
Roche, Germany 
 
 
• Ligation reaction mix (10µl sample) 
Components Concentration Company 
T4 Ligase (1U/µl) 
Ligation Buffer (10X) 
DNA 
ddH2O  
1µl 
1µl 
8µl 
10µl 
Roche, Germany 
Roche, Germany 
 
Roth, Germany 
 3.1.2 Cell culture media and reagents  
• 293FT cell line medium (based on human embryonic kidney cell line HEK): 
Components Concentration Company 
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• Mixed-glia culture basal medium  
Components Concentration Company 
BMS 
Fatal Calf Serum 
1% L-Glutamate 
1% Penisilin/Streptomicin 
1% Glucose 
 
 
10% 
1% 
1% 
1% 
 
Gibco, Germany 
PAN, Germany 
Gibco, Germany 
Gibco, Germany 
Sigma, Germany 
 
• BME-based neuronal medium 
Components Concentration Company 
BMS 
B-27 
Fatal Calf Serum 
1% L-Glutamate 
1% Penisilin/Streptomicin 
1% Glucose 
 
2% 
1% 
1% 
1% 
1% 
 
Gibco, Germany 
Gibco, Germany 
PAN, Germany 
Gibco, Germany 
Gibco, Germany 
Sigma, Germany 
 
• Other cell culture reagents 
Opti-MEM (reduced serum medium) 
Trypsin-EDTA(1X)  
Poly-L-Lysine  
Gibco, Germany 
Gibco, Germany 
Sigma, Germany
 3.1.3 Western blotting buffers and reagents 
• Preparation of lysis buffer P 
10x stock lysis buffer (500mM) 
 1x stock lysis buffer (50mM) 
Stacking gel buffer  
 
DMEM 
Fatal Calf Serum 
1% L-Glutamate 
1% Penisilin/Streptomicin 
1% Glucose 
 
10% 
1% 
1% 
1% 
1%
Gibco, Germany 
PAN, Germany 
Gibco, Germany 
Gibco, Germany 
Sigma, Germany 
Gibco, Germany Geneticin(when expanding) 
Components Concentration Company 
Tris-HCl  
all diluted in 1lit ddH2O 
30.28g 
500ml 
Roth, Germany 
Roth, Germany 
 
Components Concentration Company 
NaCl 
EDTA 
120mM 
5 mM 
0.5% 
Roth, Germany 
Roth, Germany 
 NP-40 
Components Concentration Company 
Tris –HCL, pH-6.8 
SDS 
0.5 M 
0.4% 
Roth, Germany 
Roth, Germany 
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Separation gel buffer 
Components Concentration Company 
Preparation of 100 mM PMSF in Isopropanol   M=174.19 g/mol 
Tris –HCL, pH-8.8 
SDS 
 
1.5 M 
0.4% 
Roth, Germany 
Roth, Germany 
  
174.19: 1000 ml x 100 = 17,419 g 
For 10 ml: 10 ml x 17,419 g: 1000 ml = 0.17419 g. 
• Preparation of proteinase inhibitors 
1. Stock solutions:  
Components Concentration Company 
Aporptinin 
Hepes 
Leupeptin 
2. Working solutions: 
• Thaw Aporotinin and Leupeptin on ice. 
• Put 2 µl of Aporotinin and 2 µl of Leupeptin together in eppendorf tube (on ice). 
• Centrifuge shortly and freeze at -20°C. 
I ) SDS-Gel Electrophoresis 
NuPAGE LDS Sample Buffer (4x) (Invitrogen, cat. number NP0007). 
β-mercaptoethanol (Fluka, cat. number 63689). 
II) Electrophoresis  
• NuPAGE MOPS SDS Running Buffer: 
Prestained protein marker (e.g. PageRuler™ Prestained Protein Ladder Plus from 
Fermentas, cat. number SM1811). 
NuPAGE 1ß% Bis-Tris Gel 1.5 mm X 10 well (Invitrogen, cat. number 
NPO315BOX). Power Supply. 
XCell SureLock™ Mini-Cell unique cam (Invitrogen, cat. number EI0001). 
• Blotting 
1. 10x Transfer Buffer: 
2. 1x Transfer Buffer 
PMSF 
Isopropanol 
10gm/ml 
0.01M 
5mg/ml 
100mM 
10ml
Chemicon, Germany 
Chemicon, Germany 
Chemicon, Germany 
Chemicon, Germany 
Roth, Germany 
Components Concentration Company 
MOPS 
Tris-Base, pH-7.7 
50mM 
50mM 
0.1% 
Roth, Germany 
Roth, Germany 
SDS Roth, Germany 
EDTA Roth, Germany 1mM
Components Concentration Company 
Tris-HCL 
Glycine 
ddH2O 
25mM 
192mM 
1000ml 
Roth, Germany 
Roth, Germany 
Roth, Germany 
Components Concentration Company 
10x Transfer buffer 
Methanol 
100ml 
200ml 
Roth, Germany 
Roth, Germany 
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700ml Roth, Germany ddH2O 
3. Additionally: 
Aqua bidest. Sarstedt, Germany 
Plastic tray 
Plastic tank 
Sarstedt, Germany 
Sarstedt, Germany 
Forceps 
Gel knife 
Magnetic stirrer 
Blotting membrane, e.g. nitrocellulose membrane 
Sarstedt, Germany 
Sarstedt, Germany 
Sarstedt, Germany 
 
Filter paper Bio-Rad 
XCell SureLock™ Mini-Cell unique cam  
Power Supply Invitrogen, Germany 
• Blocking the membrane 
Components Concentration Company 
1x PBS 500ml Roth, Germany 
Tween-20 250µl Roth, Germany 
Milk powder 5g 
• Primary antibody incubation 
1. Primary antibody  
2. Antibody diluent ECL Advance Blocking Agent (supplied with the ECL Advance 
Western Blotting Detection Kit from Amersham Biosciences, product code RPN2135). 
Washing the membrane 
PBS-Tween-20-Solution 
• Secondary antibody incubation 
• Washing the membrane 
PBS-Tween-20-Solution …. Roth, Germany 
• Detection 
1. ECL Advance Western Blotting Detection Kit (Amersham Biosciences, product code 
RPN2135). 
2. Photo paper (e.g. Hyperfilm™ECL from Amersham Biosciences, product code 
RPN3103K).  
 3.1.4 Antibodies   
• Primary antibodies 
Fluorophore Specificity Source Company 
CD11b  
 
SIRPβ80 
SIRPβ84 
Macrophages, 
Microglia 
- 
- 
Roth, Germany 
Components Concentration Company 
HRP labelled secondary 
antibody 
PBS - Tween-20 in Milk 
powder 
 
- 
 
5%
Chemicon, Germany 
 
Roth, Germany 
BD Pharmingen, 
DE. 
Japanese group of 
Takashi Matozaki. 
Rat 
 
Rat 
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BD Pharmingen, 
Germany 
Isotype-IgG  
 
β-tubulinIII  
IbaI 
TREM2 
Flag 
GFP 
 
Actin 
Phospho-
tyrosin 
Biot-APP 
- 
 
- 
Microglia 
- 
- 
- 
 
- 
- 
 
- 
Rat 
 
Mouse 
Mouse 
Sigma, Germany 
 
 
Sigma, Germany 
Mouse 
Mouse 
Mouse 
 
Mouse 
BD Pharmingen, 
Germany 
 
Mouse 
Mouse 
Mouse 
 
• Secondary antibodies  
Fluorophore Specificity Source Company 
FITC Mouse Goat Dianova, DE  
FITC Rat Goat Dianova, DE  
Cy3 Rat Goat Sigma, DE 
IgG & IgM, 
peroxidase  Mouse Goat Chemicon, DE 
 3.1.5 Primer sequences  
The following oligonucleotides used for PCR amplification: (All primers purchased from 
MWG, Germany) 
Target Accession number Oligo nucleotide Sequence 
    
SIRP-α NM_007547     forward 5'-CTGTTTCTGTACAGGAGCCAC-3' 
  reverse 5'-CTTCCTCTGGACCTGGACACTAGCATAC-3' 
SIRP-β1 NM_001002898 forward 5'-CCCGTTCACAGGAGAACATT-3' 
  reverse 5'-CCGGAGACCATAGGTGAAGA-3' 
18s X67238 forward 5'-ATCCATTGGAGGGCAAGTCT-3' 
  reverse 5'-CCGCGGTCCTATTCCATTAT-3' 
WRE  forward 5'-ACCGGTTAATCAACCTCTGG-3' 
  reverse 5'-GGTACCGCGGGGAGGCGGCCCAAA-3' 
β-Actin X55749 forward 5'-TGCGTGACATCAAAGAGAAG-3' 
  reverse 5'-TAGAATTACCCGCCAAGCAC-3' 
SV-40  forward 5'-CAGCAGGCAGAAGTATGCAA-3' 
  reverse 5'-CCTCGGCCTCTGCATAAATA-3' 
Egfp  forward 5'-AGCCACAACGTCTATATCATGGCCGAC-3' 
  reverse 
5'-TCACGAACTCCAGCAGTGACCATGTGAT-
3' 
DAP12  NM_011662   forward 5'-ATGGGGGCTCTGGACCCCT-3' 
  reverse 5'-TCATCTGTAATATTGCCTCTGTGT-3' 
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Table I. Real time RT-PCR primers 
• Cloning primers 
Target Accession number Oligo nucleotide Sequence 
    
IFN-γ NM_008337 forward 5’-ACTGGCAAAAGGATGGTGAC-3’ 
  reverse 5’-TGAGCTCATTGAATGCTTGG-3’ 
IL-1β NM_008361 forward 5’-ACAACAAAAAAGCCTCGTGCTG-3’ 
  reverse 5’-CCATTGAGGTGGAGAGCTTTCA-3’ 
TNF-α NM_013693 forward 5’-CCGTCAGCCGATTTGCTATCT-3’ 
  reverse 5’ACGGCAGAGAGGAGGTTGACTT-3’ 
TGF-β NM_011577 forward 5’-AGGACCTGGGTTGGAAGTGG-3’ 
  reverse 5’-AGTTGGCATGGTAGCCCTTG-3’ 
NOS2  NM_010927   forward 5'-GGCAAACCCAAGGTCTACGTTC-3' 
  reverse 5'-TACCTCATTGGCCAGCTGCTT-3' 
IL-10 NM_010548  forward 5'-AGGCGCTGTCATCGATTTCTC-3' 
  reverse 5'-TGCTCCACTGCCTTGCTCTTA-3' 
Sirpβ1-133 NM_001002898 forward 5'-CCTGCTGATTCGGGTACCTA-3'  
  reverse 5'-GACCGGAGACCATAGGTGAA-3'  
18s-134 X67238 forward 5'-CATGGCCGTTCTTAGTTGGT-3' 
  reverse 5'-GAACGCCACTTGTCCCTCTA-3' 
DAP12-120  NM_011662   forward 5'-TGCCTTCTGTTCCTTCCTGT-3' 
  reverse 5'-AATCCCAGCCAGTACACCAG-3' 
SIRP-α-320 NM_007547     forward 5'-CCGTATCAGTAATGTCACCCCAG-3' 
  reverse 5'-CTGTGCTGGAGATGTTGTAGGAG-3' 
 3.1.6 Consumables 
6 and 24-well culture plates  
15ml tubes   
50ml tubes  
5ml, 10ml, 25ml pipettes  
Chamber slides  
Cryovials  
75cm2 and 175 cm2 culture flasks  
5ml polystyrene round-bottom tubes  
3cm,10cm culture dishes  
Bacteria culture 10ml tube 
500µl, 1000µL plastic tube 
PCR tubes  
10µl, 100µl and 1000ul tips  
96 well- optical reaction plate  
CellStar, VWR International, Germany 
CellStar, VWR International, Germany 
Sarstedt, Germany 
Sarstedt, Germany 
Nunc GmbH, Germany 
VWR International, Germany 
Sarstedt, Germany 
BD Falcon, USA 
Sarstedt, Germany 
Sarstedt, Germany 
Eppendorf, Germany 
Biozym Diagnostik, Germany 
Starlab, Germany 
Microamp, Applied Biosystems, Germany 
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5ml, 10ml syringes  
Needles  
Stopcock for infusion 
Glass slices for cryosectioning  
Bottle top filters (0.25µm pore) 
Filters (0.45µm and 0.2µm pore) 
Braun, Omnifix, Labomedic, Germany 
100Sterican, Braun, Germany 
Discofix, Braun, Germany 
Menzel-Glacer, Germany 
Millipore, Germany 
  Filtropur, Sarstedt, Germany
 3.1.7 Equipment and software’s 
Centrifuges 
 
 
 
 
Cryostat 
 
Flow cytometer 
 
Electrophoresis gel chambers  
 
Power supply 
 
Heating block 
 
Incubators 
 
Laminar-Air-flow workbench 
 
Microscopes 
 
 
 
pH-meter 
 
Photometer 
 
Real time thermocycler   
 
 
Thermocycler  
 
Transiluminator  
 
Vortex 
 
 Scale 
 
-80°C Freezer  
Ultracentrifuge, Sorvall DiscoveryTM 90SE, Hitachi, 
Germany 
Megafuge, 1.OR. Heraeus, Germany 
Biofuge Fresco, Heraeus, Germany  
 
Micron HM560,  Microm Int., Germany 
 
FACSCalibur, Becton Dickinson Bioscience, Germany 
 
Blomed Analitik GmbH, Germany 
 
Amersham Bioscience, Germany 
 
Stuart Scientific, Germany 
 
Heracell240,  Heraeus, Germany 
 
Herasafe, Heraeus, Germany 
 
 Axiovert40CFL, Zeizz, Germany 
 Axiovert200M, Zeizz, Germany 
Fluoroview1000 Confocal micro., Olympus, Germany 
 Hanna Instruments, Germany 
 
Biophotometer, Eppendorf, Germany 
 
ABI Prism 5700 Sequence Detection System, 
Applied Biosystems, UK 
 
T3, Biometra, Germany 
 
Dark Reader, Clare Chemical Research, Germany 
 
2X2, VelpScientifica, Germany 
 
Sartorious, Germany 
 
Herafreeze, Heraeus, Germany 
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Magnetic stirrer 
 
Software’s 
 
 
 
 
 
 
 
Velp Scientific, Germany 
 
Openlab4.0.1, Improvision, Germany 
CorelDraw. Graphics Suite 11, Germany 
Endnote v8,Thomson ISI ResearchSoft, USA 
Microsoft Office XP, Microsoft USA, USA 
Olympus FluoView1.4. Olympus, Germany 
SDS 2.2.2, Applied Biosystems, USA 
Cellquest Pro, BD Biosciences, USA
 3.1.8 Kits and additional reagents 
• DNA and RNA purification kits 
Kit name Purpose Company 
Endofree Plasmid Maxiprep 
QIAprep Plasmid Miniprep 
Min iElute Gel extraction 
Mini Elute Clean up 
RNeasy Mini 
RNeasy Mini for lipid tissue 
Plasmid extraction (up to 500µg) 
Plasmid extraction (up to 20µg) 
DNA (70bp-4kb) extraction from agarose gels 
DNA (70bp-4kb) purification  from reactions 
Total RNA (up to 100µg) purification 
Total RNA (up to 100µg) purification from lipid 
tissue 
All from 
Qiagen, 
Germany 
• Additional reagents 
Charité, Berlin MOG35-55 (MEVGWYRSPFSRVVHLYRNGK)  
List Biological Laboratories, USA Pertussis toxin  
Difco, USA Mycobacterium Tuberculosis H37Ra  
Difco, USA Incomplete Freund’s adjuvant 
Invitrogen, Germany Lipofectamine2000 reagent   
Sigma, Germany Ampicillin  
Fluke Biochemika, Germany LB agar and LB media 
Sigma, Germany DMSO  
Sigma, Germany Glycerol  
Sakura, NL Tissue tek O.C.T. compound  
Sigma, Germany β-Mercaptoethanol  
Roth, Germany Ethanol 
Sigma, GermanyPropidium Iodide 
3.2 Animals 
Adult 6-9 week old female C57BL/6 mice were obtained from Charles River, 
Sulzfeld, Germany. For induction of experimental autoimmune encephalomyelitis (EAE), 
neuronal culture pre-natal as well as for all mixed glia culture experiments 3 to 4 days old 
post-natal mice used and further microglias were isolated from these mixed glia cultures. 
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3.3 Tissue culture 
 3.3.1 Mixed-glia culture 
75cm2 sterile flasks were used for culture. Flasks were incubated with 7ml of 
PLL overnight in the incubator at 370C for 5% of CO2. Next day, 3 to 4 days old 
postnatal mice were used for culture. Hippocampus and cortex were isolated into one dish 
of 35cm2 containing ice cold 1xPBS and then the meningers were removed and transfered 
into the sterile 15ml tube containing 5ml of ice cold 1xPBS. Working into the laminar 
flow the cells were resuspend using 5ml pipette and kept into the ice for 5 min. After 5 
minute of incubation on ice, upper part (supernatant) was transfered into a new 15ml 
tube, carefully and then centrifuged for 7min at 2500 rpm, 40C. After centrifugation, 
supernatants were aspirated and pellets were resuspended into the 5 to 6ml of basal 
medium and then cultured in 10ml mixed-glia culture basal medium containing of 75cm2 
sterile flasks and then cultured flasks were kept into the incubator at 370 C for 10% of 
CO2.  
Mixed-glia culture basal medium were changed twice a week for at least one 
month for microglia isolation. 
 3.3.2 Primary cell cultures 
Microglia was prepared from the brains of postnatal day 3 to 5 (P3 or P4) 
C57BL/6 mice as described previously (12). In brief, to collect microglial cells, the 
cultures were shaken on a rotary shaker (200 rpm) for 2 h. The detached microglial cells 
were seeded in normal culture dishes for 1 h, and then all nonadherent cells were 
removed and discarded. Purity of the isolated microglia was > 95% as determined by 
flow cytometry analysis with antibody directed against CD11b (BD Biosciences). 
Microglial cells were cultured in basal medium as described above. 
3.3.2.1 Staining of cell suspension for flow cytometry analysis 
In brief, after 2hrs of mix glia culture flask shaking cell suspension contained 
supernatant were collected. Centrifuged cell suspension in the culture tube and 
resuspended the pellet in appropriate volume of primary antibody at recommended 
dilution into the 1:200. For control, we included an isotype-matched antibody in each 
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case. After gentle vortex cells were incubated at 4°C for 30 minutes. Then, 1ml of PBS 
was added to the pellet and centrifuged at 2000 rpm for 5 minutes. Appropriate volume of 
secondary reagent such as fluorescent molecule and/or conjugated antibody at 
recommended dilution was mixed carefully and incubated at 4°C for 30 minutes. Finally, 
stained cells were washed with 1ml of PBS and centrifuge at 2000 rpm for 5 minutes and 
after centrifuge supernatant was once again discard. Resuspend the pellet in flow 
Cytometey buffer and adjusting the cell suspension to concentration of 1x106 cells/ml in 
ice cold 1xPBS in ice bucket and analysis was done with a FACS-Calibur™ flow 
cytometer (BD Biosciences). 
 3.3.3 Neuronal culture 
Primary neuronal cultures were prepared from hippocampus and cortex of 
C57BL/6 mice embryos (E15) as described previously (Neumann H, et al, 2002) and 
(Neumann et al., 1995). Briefly, neurons were isolated from whole brains of embryonic 
day 16 mice, and the meninges were removed. Cells (5 x 103/ml) were plated into dishes 
that had been pretreated with poly-L-ornithine (0.5 mg/ml; Sigma, St. Louis, MO) in 0.15 
M boric acid. Cells were cultured in chemically defined medium containing basal 
medium Eagle (BME; Invitrogen, Gaithersburg, MD) with B27 supplement [2% (v/ v), 
Invitrogen] and glucose [1% (v/v) 45%; Sigma] 
 3.3.4 Bone-marrow culture 
To isolate BM cells, mice were sacrificed, skin and muscle were removed from 
their hind limbs, ends of the bones were cut off and BM from femora and tibiae was 
flushed out using a 27 gauge needle and 5 ml syringe, and collected in 5 ml of cold 1X 
PBS. Erythrocytes were lysed using 1ml/mouse of hypotonic solution for 30 sec. 
Immediately, PBS was added preventing further lysis of white blood cells and the 
suspension was centrifuged (5 min. 2000 rpm 4°C). After a second washing step, total 
BM cells collected. RNA was isolated using RNeasy minikit (Qiagen).  
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3.4 Lentivirus based vector system 
 3.4.1 Cloning into lentiviral vectors 
Lentiviral vectors of third generation (pLenti6/V5 D-TOPO, Invitrogen) were 
used for genetic modification of cells. The CMV promoters were used and as well 
according to requirement were replaced to the phosphoglycerate-kinase (PGK), neuronal 
specific synapcin1 or microglia specific the ionized calcium-binding adaptor molecule 1 
(Iba1) gene. The genomic copy of the Iba-1 gene was located within a segment of the 
major histocompatibility complex class III region between the Bat2 and TNFα genes. 
Among the brain cells Iba-1 gene specifically expressed in microglia. Iba-1 protein is 
therefore suggested to act as an adapter molecule, mediating calcium signals that may 
function in a monocytic lineage including microglia (Kohsaka, 2005). Downstream the 
promoter, enhanced GFP (eGFP) reporter gene was inserted into the TOPO cloning sites 
or for therapeutic approach GFP was cut out using BamHI and XhoI (Roche). The mouse 
SIRPβ1 gene of 1176 base pairs (NM_001002898) and the mouse DAP12 gene of 345 
base pairs (NM_011662) (provided by E. Vivier, Centre d’Immunologie, Marseille, 
France) were tagged with the GFP gene and cloned into the pLenti6/V5 vector, 
previously amplified using extended primers was inserted. Accordingly, gene expression 
was confirmed with transfection of the packaging cell line by fluorescence imaging or 
RT-PCR (primers detailed in Materials, RT-PCR primers list). 
 3.4.2 Silencing lentiviral vectors construction 
Mostly, in our experimental set-up lentiviral vectors of the third generation, 
PLL3.7 (provided by L. van Parijs, MIT, Cambridge, MA) and pLenti6/V5 (Invitrogen) 
were used for the transduction of microglia. The mouse SIRPβ1 gene was derived from 
reverse-transcribed RNA obtained from primary cultured microglia. To analyze the 
functional characteristic of SIRPβ1 we tried to knockdown this gene by using short-
hairpin RNA interference technique in microglia cells. The correct nature of all cloned 
sequences was confirmed by automated sequencing (Seqlab) of the vectors. wSIRPβ1  
short hairpin RNA sequence 5’-TAA CTG AAG ACG GCA GGT ATT CAA GAG ATA 
CCT GCC GTC TTC AGT TTT TTT TC-3’ and mutant-type mouse SIRPβ1  short 
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hairpin RNA sequence for control study 5’-TAA GAC TTG AGC GCA GGA ATT CAA 
GAG ATT CCT GCG CTC AAG TCT TTT TTT C-3’ were inserted into the PLL3.7 
silencing vector as described by Rubinson et al. (Rubinson, 2003). For overexpression of 
SIRPβ1, we tag three times FALG tag at the N-terminal of SIRPβ1 gene in the pll3.7 
vector.  
Lentiviral transduction was performed as described previously (Rubinson, 2003). 
In brief, PLL3.7 or pLenti6/V5 vectors were purified and then cotransfected together with 
packaging vectors (Invitrogen) into 293FT cells (Invitrogen). Supernatant was collected 
after 48hrs, and viral particles in the supernatant were concentrated at 1:100 to 1:300 by 
ultracentrifugation for 90 min at 25,000 rpm (Sorvall Discovery™ 90SE Centrifuge) and 
recovered by suspension in PBS. Titers of viral particles ranged between 106 and 107 
U/ml multiplicity of infection. Purified microglia seeded at 2 x 105 cells/ml into 24-well 
plates. Lentiviral particles and 8 µg/ml polybrene (Sigma-Aldrich) were added to the 
culture and centrifuged for 90 min at 300C. Supernatant was removed immediately after 
infection and replaced with BME medium containing 10% FCS and 50% glial culture 
supernatant. In all experiments the efficiency of microglial transduction was at least 90% 
(the number of microglias, expressing the GFP molecule) as determined by 
immunocytochemistry. 
 3.4.3 Production of viral particles   
The 293FT (Invitrogen) packaging cell line were cultured in Dulbecco's Modified 
Eagle's Medium (DMEM; Gibco) with 1% penicillin/streptomycin and glucose (Sigma) 
at 37°C in 10% CO2.  
In order to produce viral particles, 5 million 293FT cells were seeded in 10 cm 
dishes precoated with poly-L-Lysine (Sigma). After removing the culture medium and 
washing once with PBS, 5 ml of Opti-MEM medium (Gibco) without antibiotics were 
added. Cells were transfected using the gene-containing vector together with three 
packaging helper plasmids and Lipofectamine 2000 reagent (Invitrogen). The principle of 
this procedure is the entrance of the DNA to the cells after forming lipidic complexes 
form with the Lipofectamine2000 reagent. Medium was replaced for fresh DMEM 10 hrs 
post-transfection. Viral supernatant (10ml) was collected at 48-72 hrs post-transfection. 
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To increase viral titres, particles were concentrated by ultracentrifugation (25000 rpm for 
1hr and 30min at 4°C) using a Sorvall DiscoveryTM 90SE ultracentrifuge. Supernatant 
was removed, and pellet resuspended by slightly shivering the tubes overnight at 4°C in 
250µl of medium. Particles were used immediately for transduction or frizz down in -
800C. 
3.5 Microglia transduction 
 Microglia cells were isolated from mixed-glial culture. The cultures were shaken 
on a rotary shaker (200-400 rpm) for 2 h. Supernatants contained microglia cells 
suspension were centrifuged for 1500 rpm for 5 min. at 4°C. After, removal of 
supernatant 200µl of BME medium were added to the pellet and transduced using fresh 
or -80°C frozen concentrated viral particle along with concentration of 1µg/µl of 
Polybrene (final concentration approximately 8 µg/ml polybrene (Sigma-Aldrich)) in to 
the one well of 24 well- culture-dish. 24 well-culture-dishes were centrifuged at 3000 
rpm for 90 min. at 30°C. Media changed to fresh BME after centrifugation. 
 3.6 Immunocytochemistry 
 3.6.1 Immunocytochemical labelling of microglia cells 
Microglia was fixed in 4% paraformaldehyde for 1 h, blocked by 1% BSA/PBS 
for 2 h, and then immunostained with a purified monoclonal rat antibody directed against 
SIRPβ1 (SIRPβ-80 and SIRPβ-84) (provided by Takashi Matozaki, Gunma University, 
Japan) and a secondary fluorescence goat-anti-rat-Cy3 antibody directed against rat IgG 
(1:200; Dianova). To identify the cell type, cells were double labelled with monoclonal 
mouse antibody directed against CD11b followed by a secondary fluorescence FITC-
conjugated antibody directed against mouse IgG. Images were collected by confocal laser 
scanning microscopy with a 40x objective (Olympus). 
 3.6.2 Immunocytochemical labelling of neuronal cells 
Microglia was fixed in 4% paraformaldehyde for 1 h, blocked by 1% BSA/PBS 
for 2 h, and then immunostained with a purified monoclonal rat antibody directed against 
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SIRPβ1 (SIRPβ-80 and SIRPβ-84) (provided by Takashi Matozaki, Gunma University, 
Japan) and a secondary fluorescence goat-anti-rat-Cy3 antibody directed against rat IgG 
(1:200; Dianova). To identify the cell type, cells were double labelled with monoclonal 
mouse antibody directed against beta-tubulin1 followed by a secondary fluorescence 
FITC-conjugated antibody directed against mouse IgG. Images were collected by 
confocal laser scanning microscopy with a 40x objective (Olympus). 
 3.6.3 Immunocytochemical labelling of astrocytes  
Microglia was fixed in 4% paraformaldehyde for 1 h, blocked by 1% BSA/PBS 
for 2 h, and then immunostained with a purified monoclonal rat antibody directed against 
SIRPβ1 (SIRPβ-80 and SIRPβ-84) (provided by Takashi Matozaki, Gunma University, 
Japan) and a secondary fluorescence goat-anti-rat-Cy3 antibody directed against rat IgG 
(1:200; Dianova). To identify the cell type, cells were double labelled with monoclonal 
mouse antibody directed against GFAP followed by a secondary fluorescence FITC-
conjugated antibody directed against mouse IgG. Images were collected by confocal laser 
scanning microscopy with a 40x objective (Olympus). 
3.7 Microglia chemokine and cytokine stimulation 
To analyze functional properties of SIRPβ1 primary microglia cells were isolated 
and purified from postnatal mouse brain tissue as reported before. Activation of these 
cells was done with tumour necrosis factor-alpha (10ng/ml), tumour necrosis factor-beta 
(103U/ml), interferon-gamma (100 U/ml) and LPS (1mg/ml) also incubated for 48 and 72 
hours at 37°C in 10% CO2. After incubation, RNA was isolated and prepared for cDNA. 
Inflammatory mediators could induce gene transcription of SIRPβ1 and DAP12 in 
primary microglia were quantitatively analysed by real time PCR. 
3.8 Western blotting  
For Western blotting, 293 cells (Invitrogen) were cotransfected with the fSIRPβ1 
plus DAP12-GFP plasmids. Cells were added to culture dishes coated with the antibody 
directed against the Flag epitope or control antibody and shortly centrifuged. After 10 
min the cells were lysed, and the total protein lysate was analyzed with antibody specific 
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for tyrosine phosphate (4G10; Upstate Biotechnology) by NuPAGE electrophoresis 
system (Invitrogen) and ECL Advance Western Blotting Detection Kit (Amersham 
Biosciences). In a second step, the membrane was reblotted with antibody directed 
against GFP (BD Biosciences), Flag (Sigma) and beta-actin (AbCam) as a positive 
control. 
3.9 Induction of Experimental Autoimmune 
Encephalomyelitis 
 3.9.1 Animals 
Adult 6-9 week old female C57BL/6 mice were obtained from Charles River, 
Sulzfeld, Germany. For induction of experimental autoimmune encephalomyelitis (EAE), 
mice were injected in the tail base bilaterally with 200 μl of an innoculum containing 100 
μg of MOG35-55 (amino acids MEVGWYRSPFSRVVHLYRNGK; Seqlab) and 1 mg 
Mycobacterium tuberculosis H37 Ra (DIFCO, Detroit, MI) in incomplete Freund 
adjuvant (DIFCO). Pertussis toxin (200 ng; List Biological Laboratories, Campbell, CA) 
was injected on day 0 and day 2 of immunization. Clinical signs were scored as 
following: 0, no clinical signs; 1, complete limp tail; 2, complete limp tail and abnormal 
gait; 3, one hindlimb paralysis; 4, complete hindlimb paralysis; 5, fore- and hindlimb 
paralysis or moribund. Only mice having disease onset (clinical score of one or more) on 
day 14 were used for experiments. Mice were sacrificed for histopathology and RNA was 
isolated at day 14.  
 3.9.2 Myelin Oligodendrocyte Glycoprotein (MOG) emulsion  
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; Charité, Berlin) was 
emulsified with 1 mg of Mycobacterium Tuberculosis H37Ra (Difco, Detroit, MI) in 
incomplete Freund’s adjuvant (Difco). Emulsion was left overnight at 4ºC before mice 
immunization. 
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 3.9.3 Immunization of animals with MOG35-55 peptide 
For immunization protocol, adult 6-8 weeks old female C57Bl/6 mice were 
anesthetized and injected subcutaneously in both inguinal lymph node regions with 200 
µg of MOG35-55 emulsion.  
PTX (200 ng, List Biological Laboratories, Campell, CA) was injected on day 0 
(intravenously) and 2 (intraperitoneally). Weight and clinical score of animals was 
checked daily for at least 30 days thereafter unless moribund     
Scoring of clinical symptoms was as follows: 
 
0 1 2 3 4 5 
healthy   limp tail 
hind limb 
 paralysis 
2hind limb 
 paralysis 
 Forelimb 
paralysis 
death 
Clinical Scores 
 
0- Healthy,  1- Complete limp tail, 2- Weakness of hind limbs, 3- Paralysis of hind limbs 
4 - Weakness and paralysis of fore limbs and 5 - Death. 
Animals with a clinical score less than 1 by day 14 post-immunization were not used for 
the study. 
3.10 Immunohistochemistry 
 3.10.1 Immunohistochemistry labelling in EAE and APP sections 
 To demonstrate the presence of SIRPβ1 in microglia cells and splenocytes, we 
investigated brains, spinal cords and spleens from 7-8 weeks old, female C57BL/6 mice 
(n=12) in experimental autoimmune encephalomyelitis (EAE) model. The animals were 
intravenously injected by PBS (n=6, control group) or MOG 35-55 antigen (n=6, 
experimental group) to induce EAE. The mice were treated in agreement with the 
German law on the use of laboratory animals. They were observed on daily basis with 
weight determination and evaluation of the clinical symptoms of EAE. At day 16th (the 
peak of the disease), the mice were anesthetized with 1.25% solution of avertin. A 
perfusion fixation of the animals was performed transcardinally with tris buffered saline 
(TBS) with heparin (pH 7.4) followed by the injection of 0.1 M Phosphate buffered saline 
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(PBS) (pH 7.4) containing 4% paraformaldehyde. Subsequently, brains, spinal cords and 
spleens were removed and fixed in a 4% paraformaldehyde solution at 4°C for one day, 
passed in 15% and 30% sucrose in PBS, frozen in liquid nitrogen and then stored at - 
20°C. The hemispheres, the cerebellum, the spinal cord and the spleen were cut with a 
cryostat in 4 µm and 20 µm thick sections on glass slides and stored until use at -20°C.  
After blocking for endogenous peroxidase activity with H2O2-methanol and for 
unspecific protein interactions with 10% bovine serum albumin 4µm thick paraffin and 
20µm thick fresh-frozen sections were immunostained with a purified antibody directed 
against SIRPβ1 (SIRPβ-80 and SIRPβ-84; monoclonal rat, 1:200). Primary antibody in 
paraffin sections was detected with biotinylated secondary antibody, ABC-complex 
(Biomeda, Foster City, CA, USA), and 3, 3-diaminobenzidine-HCl (Sigma-Aldrich, 
Taufkirchen, Germany). Counterstaining with hematoxylin was performed afterwards. 
SIRPβ1 in fresh-frozen sections was detected with Carbocyanin Cy3-labeled anti-rat IgG 
secondary fluorescence antibody (Dianova, Hamburg, Germany). Sections were mounted 
in Corbit-Balsam (Hecht, Hamburg, Germany) or in molwiol and viewed with a Leica 
DMBL light and fluorescence microscope (Olympus, Germany). Images were collected 
by confocal laser scanning microscopy with 40x or 60x objectives (Olympus). Negative 
control was carried out.  
 3.10.2 Immunohistochemistry labelling in brain microglia 
To identify the cell type, double-label immunofluorescence and confocal laser scan 
microscopy were performed with antibodies directed against SIRPβ1 and Iba1 (rabbit, 
1/200; Wako, Japan). The primary antibodies were detected with Cy3-labeled anti-rat 
IgG and FITC--conjugated anti-rabbit IgG (Dianova, Hamburg, Germany) secondary 
fluorescence antibodies. Sections were mounted in molwiol and viewed with the 
Olympus laser scanning confocal microscope (Olympus).  
3.11 Real-time PCR analysis from EAE and APP mice 
specimens 
For analysis in specific part of mice for SIRPβ1and DAP12 expression following 
in EAE, APP and control mice were sacrificed. Brain, cerebellum, spinal cord and spleen 
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were removed carefully. RNA was isolated by the RNeasy Mini Kit lipid tissue (Qiagen) 
and reverse transcription was performed as described in section (3.11.1). Levels of the 
same SIRPβ1 and DAP12 were determined separately in EAE, APP and control. 
3.11.1 RNA extraction, reverse transcription and real-time PCR 
quantification 
RNA was isolated from cell-culture using RNeasy minikit (Qiagen). The principle 
of the procedure of this kit is the selective binding of RNA to a silica membrane while 
the rest of the cell components are washed away. 
As starting material from 20,000 to 1 million cells from each cell samples were 
disrupted by addition of buffer containing β-mercaptoethanol 1% (Sigma) and 
homogenized to reduce viscosity of lysates. Afterwards, ethanol 70% was added to 
provide proper binding conditions to the silica-gel membrane of the columns provided by 
the kit. Finally, RNA molecules longer than 200 nucleotides eluted in 25µl of water to 
obtain DNA copy (cDNA), reverse transcription (RT) was performed using 
approximately 3µg of RNA isolated as described above. Superscript III reverse 
transcriptase enzyme (Invitrogen) and hexamer random primers (Roche) were used for 
this reaction during 1 hour at 50°C. The product of this synthesis was utilized as template 
for the relative quantification step. As control of possible genomic DNA contamination, 
samples without the reverse transcriptase enzyme were prepared. 
Real time quantitative Polymerase Chain Reaction (PCR) was performed using an 
ABI Prism 5700 Sequence Detection System machine (Applied Biosystems), which 
detects fluorescent signal coming from a reporter during the PCR amplification reaction. 
SYBR green (emits signal only when intercalates in double stranded DNA) was the 
fluorescent dye of choice which is included in the PCR master mix (Applied Systems) 
together with the polymerase enzyme (AmpliTaq Gold). The amplification protocol for 
the GeneAmp 5700 Sequence Detection System Software (v.2.2) was performed. Cycles 
were as follows: initial denaturation at 95°C for 10 min, denature at 95°C for 15 sec., 
annealing and amplification at 60°C for 1 min. repeated 40 times. Non-template control 
and negative samples from reverse transcription were included. Ribosomal subunit 18s 
(18s) was used as endogenous gene expression control. After the reaction, the melting 
curve program was performed to assess the presence of specific products. A peak in the 
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negative first derivative of the fluorescence versus temperature graph indicated a unique 
specific product in the amplification reaction.  
3.12 Phagocytosis assay  
  3.12.1 Phagocytosis assay of apoptotic neurons and splenocytes 
Primary microglia cells were lentivirally transduced with shSIRPβ1 and 
shControl. After transduction microglia was cultured for 72h to achieve effective 
knockdown of SIRPβ1 by RNA interference. Neurons were cultured for 5–10 days and 
splenocytes for 2 days then okadaic acid at the final concentration of 30 nM was added 
and incubated for 3 h to induce apoptosis. Neuronal and splenocytes cell membranes 
were labelled with CellTracker CM-DiI membrane dye at the final concentration of 
2µg/µl (Molecular Probes). After incubation, apoptotic neurons and splenocytes were 
washed two times with 1x PBS and added to the transduced microglial culture at an 
effector/target ratio of 1:20. At 1 and 24 h after addition of apoptotic neurons and 
splenocytes, the number of microglia having phagocytosed neuronal and splenocytes cell 
membranes were counted using a confocal fluorescence microscope (Olympus). 
Apoptotic cells were counted in three different areas at a 10x magnification. The amount 
of phagocytosis was confirmed by quantifying phagocytosed cells. 
  3.12.2 Beads phagocytosis assay 
Microglia was transduced with the fSIRPβ1 and the GFP control vector. Cells 
were cultured on dishes, which are precoated with 10 µg/ml antibody directed against the 
Flag epitope (Sigma-Aldrich) or 10 µg/ml isotype control antibody (Sigma-Aldrich). 
After 24 h, 1.00 µm of red fluorescent microsphere beads (Fluoresbrite Polychromatic 
Red Microspheres; Polysciences Inc.) were added for 1 h. Phagocytosis of microsphere 
beads by microglia was analyzed by fluorescence microscopy. Furthermore, the 
percentage of microglia having phagocytosed beads was determined. Because 
phagocytosis varied from one experiment to the other, the relative change in phagocytosis 
was determined. Data are shown as the relative change in phagocytosis between 
microglia cultured on antibody directed against the Flag epitope and control antibody. 
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  3.12.3 Amayloid beta conjugated phagocytosis assay 
Microglial cells were prepared from brains of postnatal (P3–P4) C57BL/6J mice. 
To collect microglial cells, the mixed glia culture were shaken on a rotary shaker (350 
r.p.m.) for 2 h. Primary microglia cultured was maintained in a 24-well plate at a density 
of 3 x 105 cells per well. Every individual experiment primary microglia was tranduced 
with pll3.7 RNA interference mediated Sh-SIRPβ1-GFP plasmid. As a control, Primary 
microglia were tranduced with ShSIRPβ1-Control-GFP which is scrambled sequence of 
silencing peptide and an empty plenty-GFP plasmid respectively. These respectively 
transduced cultures were treated with biotinylated Aß42 peptide (10 µg/ml) (human 
amyloid-β peptide 1–42 conjugated at the N-terminus with biotin) from Bachem 
(Heidelberg, Germany) for overnight.  To demonstrate that uptake of Aβ42 involves 
phagocytosis, cells were fixed in 4% paraformaldehyde and then permeabilized with 0.2% 
Triton-100. Fixed cells were incubated with Cy3-conjugated streptavidin (Amersham). 
24-well culture plate were washed with 1x Phosphate buffer saline several times and kept 
at 4°C in the dark until analysis made under a laser scanning confocal microscopy  
(Leica LSC, Heidelberg, Germany).  
  3.12.4 Cy3 conjugated myelin phagocytosis assay.  
Primary microglia cultured in a 24-well plate at a density of 3 x 105 cells per 
well were tranduced with pll3.7 RNA interference mediated Sh-SIRPβ1-GFP plasmid. As 
a control Primary microglia were tranduced with Sh-SIRPβ1-Control-GFP which is 
scrambled sequence of silencing peptide and an empty plenty-GFP plasmid. Transduced 
microglia were treated with Cy3-labeled mouse myelin (2 µg/ml) for 6 hrs. After 6hrs 
incubation in 10% Co2 at 370C cells were washed with 1x Phosphate buffer saline several 
times to get rid of Cy3-labeled myelin which was not phagocytosed by microglia. 
Analysis of myelin phagocytosis was done after 24hrs under a laser scanning confocal 
microscope (LSC; Leica, Heidelberg, Germany). 
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3.13 Appendix to Materials and Methods 
 
 • RNA Isolation 
Isolation of RNA was performed using the RNeasy Mini Kit (Qiagen, Germany). The 
protocol used is summarized as follows: 
• Take eppendorf with tissue (e.g. 20-30mg in PBS). 
• Add 700µl lysis buffer (inc. 1:100 β-mercaptoethanol), use 350µl if less than 20mg of 
tissue or less than 5x106 cells (lysis buffer lasts approx. 1 month). 
• Homogenize with small syringe (use large first if a lot of tissue). Centrifuge (3min, 
max). 
• Mix 600µl of supernatant with 600µl EtOH (70% in dd H2O). 
• Add 700µl into column and centrifuge (15s, 10000rpm), throw away waste, add rest of 
mixture and repeat. 
• Add 350µl wash buffer RW1 and centrifuge (15s, 1000rpm), throw away waste. 
• Mix 10µl DNase1 with 70µl RDD buffer, add to filter and leave for 15min. 
• Add 350µl wash buffer RW1 and centrifuge (15s, 10000rpm), throw away waste. 
• Add 500µl wash buffer RPE (+EtOH) and centrifuge (15s, 10000rpm), remove waste, 
repeat and centrifuge (2min, max). Remove waste and centrifuge again to dry (1min, 
max). 
• Place column in eppendorf, add 35µl RNase free H2O (onto filter), leave for 3 min, 
centrifuge (1min, 10000), throw away column. RNA is collected in eppendorf. 
• Measure concentration (µg/ml) and RNA/protein absorption (260/280) using 
photometer (Eppendorf), and dilute with ddH2O accordingly to start with about 3µl of 
sample RNA. 
 
• Polymerase Chain Reaction (PCR) 
Polymerase chain reaction was performed for the amplification of specific cDNAs in 
order to obtain gene products for insertion into viral expression constructs, as well as for 
analysis of sequences inserted into such constructs following mini-prep plasmid 
preparation. 
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In cases where correct sequences were required a polymerase with high proofreading 
ability was used, Vent Polymerase (New England Bio Labs), whereas in cases of analysis 
a standard Taq Polymerase was used (Roche). A master mix was prepared containing all 
required reagents (see Materials, buffers and solutions) and aliquot to PCR tubes 
according to the following protocol: 
• Add 47.5µl master mix to each tube. 
• Add 2µl of appropriate cDNA (nothing to –ive control). 
• Place tubes into PCR machine and choose required program (use heated lid!). 
Example of program: 
Initial Denaturation Step:  94oC 3min 
Cycle Step 1 – Denaturation: 94 oC 1min 
Cycle Step 2 – Annealing 55-60 oC 1min (dependent upon primers used) 
Cycle Step 3 - Elongation 74 oC 1min (3min for Vent Polymerase) 
Repeat cycle steps accordingly between 15 to 35 times. 
Final Elongation Step: 74 oC 3min. 
PCR products were either stored at 4oC or ran on a 1% agarose gel for analysis or 
extraction of the product. 
 
• Agarose Gel Analysis and Extraction 
In order to observe PCR products they were run on a 1% agarose gel. For analysis, 
ethidium bromide was added to the gel to allow visualization under a UV-lamp. Where 
ever extraction of the product was required, “Gelstar” (BioWhittaker Molecular 
Applications) was used instead of ethidium bromide to allow visualization without the 
use of an UV- lamp and thus preventing the possibility of mutation. After setting the gel 
in the chamber (see Materials, buffers and solutions) proceed as follows: 
• Add a mixture of 3µl loading dye and 6µl sample to each lane, using a ladder in one 
lane to evaluate product size. 
• Connect to power supply and set to 120V, 110A for 30min. 
• Visualize DNA under a UV-lamp. 
• For extraction, visualize using a Dark Reader transiluminator, cut out required fragment 
and extract DNA. 
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Extraction of DNA from agarose was performed using the QIAquick Gel Extraction Kit 
(Qiagen) as follows: 
• Excise DNA fragment and weigh. 
• Add 3xVol buffer QG to 1xVol gel (max 400mg, normally use 450µl). 
• Leave at 50oC for 10 min (vortex every 3min). 
• Add 1xVol isopropanol (normally use 150µl), invert several times, place in column, 
centrifuge 1min, discard flow through. (Qiagen column collects fragments within range 
of 70bp-10Kb). 
• Add 500µl QG buffer, centrifuge 1min, and discard flowthrough. 
• Add 750µl buffer PE, centrifuge 1min, discard flowthrough, and repeat centrifugation. 
• Place column in clean tube, add 10µl EB buffer/H2O, leave 1min, and centrifuge 1min. 
 
• Real-time RT-PCR  
Pipette reaction mix accordingly prepared (see Materials, buffers and solutions) into 
wells. Add 1 µl of cDNA. Use a “non-template control” (NTC) well only with master 
mix. When pipetting, avoid bubbles. Cover the plate, with the plastic lid. 
Program on ABI Prism SDS 7000 (Standard Protocol)  
Cover T°= 105°C!! Initial denature: 95°C, 10min 
Denature: 95°C, 15sec 
Annealing: 60°C, 60sec 
Amplification for 40 cycles 
Final elongation: 72°C, 10min 
To asses if a specific product was obtained, perform dissociation curve analysis. 
(95°C, 60°C, 95°C ramp rate 2%). 
(Alternatively, the PCR outcome can be examined by 3% agarose gel using 5 μl from 
each reaction)  
Analyze the real-time PCR result with the SDS 7000 software. Check to see if there is 
any bimodal dissociation curve or abnormal amplification plot. 
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• Ligation 
Ligation of insert into plasmid was performed using T4 DNA Ligase (Roche). Ligation 
reactions were normally carried out at 15oC for at least 3 hours. The reaction mix used 
was as listed below. Normally a ratio of 1:3 or 1:15 was used for plasmid: insert DNA in 
a volume of 8µl. 
 
• Transformation 
Chemically competent bacteria (TOP10 Chemically Competent E.Coli, Invitrogen) were 
transformed with ligated insert-plasmid DNA and expanded according to the following 
protocol: 
• Defrost chemically competent cells on ice (500µl per tube). 
• Aliquot 100µl of cells per transformation and leave on ice for 30min. 
• Dilute ligation mix 1:1 and add 0.6µl to 100µl of competent bacteria. 
• Heat-shock cells at 42oC in water bath for 1min. 
• Return cells to ice for 2min.  
• Add 1ml LB medium and incubate in for 45min at 37oC (rotatory shaker, >200rpm). 
• Centrifuge for 3min at 7000rpm and remove excess medium. 
• Plate onto appropriate selective LB plates and incubate at 37oC overnight. 
• Pick colonies and grow in selective LB medium for 10hr at 37oC in shaker. 
• Isolate plasmid DNA using mini-prep kit (Qiagen). 
• Verify ligation by restriction digest and PCR. 
• Prepare high concentrate stock of positive samples using maxi-prep kit (Qiagen). 
 
• Transfection 
Transfection of cell lines was performed to produce lentiviral particles as well as to 
confirm the expression of genes cloned into plasmids. Lentiviral particles were produced 
by co-transfection of the lentiviral plasmid along with plasmids expressing accessory 
lentiviral genes into a packaging cell line using a lipofectamine-based technique as 
follows: 
• Plate 5x106 293FT cells in a poly-L-lysine coated 10cm dish one day before 
transfection to obtain a culture of 80-90% confluence. 
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• On the day of transfection add antibiotic-free medium to the cells (10ml). 
• Prepare DNA-lipofectamine complexes: 
9µg packaging mix + 3µg vector in 1.5ml Opti-MEM medium (Gibco). 
36µl Lipofectamine 2000 (Invitrogen) in 1.5ml Opti-MEM 
leave for 5min at room temperature. 
mix gently and leave for 20min at room temperature 
• Add transfection mix to cells dropwise, mix gently and leave for 6 hours. 
• Add medium containing antibiotics and 2% serum to the transfected cells. 
• Remove supernatant 36-72hrs post-transfection and pellet the debris. 
As the lentivirus is VSV-G pseudotyped, the supernatant may be stored overnight at 4oC, 
frozen at -80oC or concentrated by ultracentrifugation (25,000rpm, 4oC, and 90min). 
 
• Transduction 
A number of different transduction protocols can be used depending upon the target cell. 
Cells at a confluence of 30-50% were treated with lentiviral supernatant and kept at 37oC 
overnight. Fresh medium was added to the cells on the following day. 
Expression normally reached its peak 48hr post-transduction. 
 
• Supernatant Spin Infection (cell lines) 
Cells at a confluence of 30-50% in 6-well dishes were treated with lentiviral 
supernatant, centrifuged (2500rpm, 30oC, 2x - 45min) and kept at 37oC overnight. 
Fresh medium was added to the cells on the following day. Expression normally reached 
its peak 48hr post-transduction and was generally higher than that observed following 
regular supernatant treatment. 
 
• Viral Concentrate (primary cell culture and cell lines)
Viral particles concentrated by ultracentrifugation were resuspended overnight at 4oC in 
300µl serum free medium (e.g. Stem Span). The resuspended viral concentrate was added 
to the target cells and kept at 37oC overnight. Fresh medium was added to the cells on the 
following day. Expression normally reached its peak 48hr post-transduction and was 
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generally higher than that observed following regular supernatant treatment or spin 
infection. 
 
• Concentrate Spin Infection (primary cell culture and cell lines)
Viral particles concentrated by ultracentrifugation were resuspended overnight at 4oC in 
300µl serum free medium. The resuspended viral concentrate was added to the target 
cells, centrifuged (2500rpm, 30oC, 90min) and kept at 37oC overnight. Fresh medium was 
added to the cells immediately after the following centrifugation. Expression normally 
reached its peak 48hr post-transduction and was generally higher than that observed 
following other transduction procedures. 
 
Kill Curve 
The pLenti6/V5 plasmid expresses the antibiotic blasticidin to allow selection of 
transduced cells in culture. The following protocol was used to determine the minimum 
concentration of balsticidin required to kill non-transduced cells: 
• Plate cells in a 6-well plate at a confluence of 25%. 
• Add blasticidin at various concentrations, e.g. 0, 2, 4, 6, 8, 10 µg/ml. 
• Change medium every 3-4 days. 
• Observe the percentage of surviving cells. 
• Determine the lowest concentration that kills all cells within 10 days of treatment. 
 
Viral Titre Determination 
Titration of the viral titre may be performed using FACS analysis to quantify the number 
of transduced cells in order to estimate the concentration applied to primary 
hematopoietic cultures. Cells (can be from a cell line like HeLa) are transduced as 
follows: 
• Plate 5x104 cells per well in a 6 well culture dish. 
• Prepare 10-fold serial dilutions of viral stock (10-6, 10-5, 10-4, 10-3, 10-2, 0). 
• Add to cells in total volume of 2ml medium containing 6µg/ml polybrene. 
• Leave overnight at 37oC. 
• Add fresh medium and leave overnight at 37oC. 
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Transduced cells were allowed to culture for 4 days following transduction and then 
analyzed by FACS (normally best done using a GFP reporter gene construct). Only 
dilutions yielding to 1-20% GFP-positive cells should be considered for titer calculations. 
Below 1%, the FACS may not be accurate enough to give a reliable determination of the 
number of GFP+ cells. Above 20%, the chance for each GFP+ target cell to be 
transduced twice significantly increases, resulting in underestimation of the number of 
transducing particles. The following formula is used to calculate the viral titre:  
Titer (Hela-transducing units / ml) = (5x104 Hela cells) x (% GFP-positive cells/100)
                                                                     Volume of supernatant (in ml) 
Protein extraction procedure: 
 
293FT cells were used for protein extraction; all medium were removed from 10cm 
culture dish and washed once with ice-cold 7ml of 1x PBS with 70 µl PMSF and 
incubated for 2-3 min. Abrade twice the adherent cells with a cell scraper then slightly 
resuspend the suspension with 5 ml pipette. Every thing was kept into 15 ml tube and 
washed the dish with 3 ml PBS and centrifuged 15 ml tube (10 min, 1800 rpm, 4°C). 
After centrifugation, remove a supernatant and resuspend a pellet in lysis buffer P with 
proteinase (Shortly before use add 1 ml lysis buffer P into the tube with Aporotinin and 
Leupeptin.) and cells were lysed for 30 min at 4°C. The lysates were transfer into 
eppendorf and centrifuged at 15 min, 13000 rpm, 4°C, the resulting supernatant were 
subjected to measure a protein concentration by Bradford’s method or freeze at -20°C. 
Final concentrations were used for immunoblot analysis. 
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4. Results 
4.1. Flow cytometry analysis of microglial cells isolated 
from mixed glial culture 
 
To assess the purity of the microglial population from mixed glial cell culture 
system and to show specificity of the desired cells, we performed flow cytometry 
analysis. Microglia cells were labelled with biotinylated CD11b as well as with control 
IgG specific primary antibodies. Staining was followed by a secondary antibody 
conjugated to a fluorescent molecule. 
The microglial cell population was obtained by a specific selection (Fig 4.1). 
Therefore, the depletion method selected in this work shown to be a trustworthy protocol 
to obtain a microglial enriched cell population. 
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 Figure 4.1. Microglial population were found to be positive for CD11b (up to >90%)  
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4.2. SIRPβ1 and its adaptor protein DAP12 expression 
analyzed in primary cultured microglia by RT-PCR.  
SIRPβ1 in primary microglial cells was completely unknown to scientific 
community. In the patients with the inflammatory Nasu-Hakola brain disease which 
identified as a genetic mutation in DAP12. It appears that DAP12 is expressed in case of 
microglial activation in the CNS. Therefore, we analyzed SIRPβ1 that is DAP12 
associated receptor in primary microglial cells. The primary microglia cells were isolated 
and purified from postnatal mouse brain tissue. Gene transcripts of SIRPβ1, DAP12 and 
18s (as housekeeping control gene) were analyzed by RT-PCR in cultured primary 
microglial cells. Total RNA was prepared from cultures of microglia, neurons, bone 
marrow derived myeloid cells and splenocytes. Gene transcripts for SIRPβ1 and DAP12 
were detected in microglia, bone marrow derived myeloid cells and splenocytes, but not 
in cultured neurons (Fig. 4.2). 
Neuronal cells Microglial cells 
  
  1 2 3 4 5 1  2   3   4   5 
   
Splenocytes
  1  2   3   4   5
Myeloid cells 
  1  2   3   4   5   
1-250 marker  
2-SIRPB1 
3-DAP12 
4-18s 
5-Negative control 
   
Figure 4.2. Analysis of SIRPβ1 and DAP12 gene transcripts demonstrated a 
transcription of SIRPβ1 and DAP12 in microglia, myeloid cells and splenocytes, 
but not in neurons.
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4.3. SIRPβ1 expression analysis in primary cultured 
microglia by immunocytochemistry  
Subcellular expressions of SIRPβ1 were analyzed in different cell culture system 
by immunocytochemistry and confirmed by confocal microscopy. CD11b and IgG an 
isotype control were used as primary antibody for co-immunostaining and confirmed not 
only staining protocol but also antibodies specificity (Fig. 4.3 A). Immunolabelling of 
SIRPβ1 was detected as a cytoplasmic staining in cultured mircroglia using monoclonal 
antibodies directed against SIRPβ1 (SIRPβ80 and SIRPβ84, respectively) (Fig. 4.3 A). 
Interestingly, no immunostaining of SIRPβ1 was detected in cultured neurons double-
labelled with antibodies directed against β-tubulin-III (Fig. 4.3 B and C). 
A 
Resting microglia with only Goat-anti-rat Cy3 rat-anti-mouse_Cy3                 Resting microglia_CD11b + 
 
  
Resting microglia+ Goat-anti-rat_                  Resting microglia+ Goat-anti-rat_SIRP80+ Cy3     SIRP84+ Cy3  
  Figure 4.3. (A): SIRPβ1 protein was detected by immunofluorescence labeling 
in primary microglia, double-labeled with CD11b. Scale bar: 20μm  
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B 
 
 
 
 
C 
 
 
 
 
Figure 4.3. (B and C): No SIRPβ1 signal was detected after using a 
 control antibody or in cultured neurons. Scale bars: 20μm. 
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4.4. Lentiviral vectors and microglial transduction 
 
Viral vectors were used to genetically manipulate the cell population we were 
interested, which contain a fluorescent marker (eGFP) (scheme on figure 3.4.1).  
A) 
 
B) 
 
 
Figure 3.4.1. Schematic representation of the constructs. 
Lentiviral vector backbone, the CMV promoter was used for 
experimental setup. Pll3.7 vector was modified for 3xflag-
mSIRPb1 (A) pLenti6/V5 D-topo plasmid was modified for 
DAP12 gene integration. As well downstream, the eGFP gene 
was inserted between the TOPO cloning sites (B).  
 
 
In these vectors the gene of interest is under the control of the CMV promoter. 
Although intricacies for modifying cells using lentivirus derived vectors under our 
experimental conditions were faced before, the system was tested for assessing the 
percentage of microglial cells expressing the reporter gene after transduction. 
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First, the vector expressing eGFP was used to transfect the packaging cell line 
293FT in order to prepare viral particles. Upon transfection almost 100% of the 
packaging cell line was positive for eGFP (fig 3.4.2). 
 
 
Figure 3.4.2. Upon transfection using a CMV promoter driven eGFP 
expression lentiviral construct, the packaging cell line 293FT was 
100% positive for eGFP expressing cells. Scale bar: 20 um. 
 
 
After selection, isolated microglia was transduced with the eGFP containing viral 
particles produced as described above in 293FT cells. When using non-ultracentrifuged, 
freshly collected from the packaging cells line viral supernatant (106 TU/ml), less eGFP 
expression was observed in the microglia (as was checked after 24 hours. Transduced 
293FT cell line as procedure control showed 100 % eGFP positive cells (fig 3.4.2). 
Thereafter, a protocol to augment viral titer (108-109 TU/ml) was chosen. Viral fresh 
supernatants were ultracentrifuged and the pellet containing viral particles were 
resuspended in a low volume of media (500μl). Efficiency of microglial cell transduction 
using these concentrated viral particles was analyzed by flow cytometry (Fig 4.1). One 
day after incubation with the concentrated viral particles up to >90 % of cells were 
positive for eGFP (figure 4.1). Further cell transduction has been in the range of this 
value.  
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4.5. Upregulation of SIRPβ1 in primary cultured 
microglia by interferon’s 
 
To begin defining the role of SIRPβ1 expression in functionally modulating 
microglial activation, we chose to use the common postnatal brain-derived microglia 
culture system for these studies. We have shown, whether inflammatory mediators could 
induce gene transcription of SIRPβ1 and DAP12 in primary microglia, we treated the 
cells with tumour necrosis factor-alpha (10 ng/ml), tumour necrosis factor-beta 
(103U/ml), interferon-gamma (100 U/ml) and LPS (1mg/ml) for 72 hrs at 37°C in 10% 
CO2. Indeed, treatment with inflammatory mediator’s up-regulated gene transcription of 
SIRPβ1 and DAP12. At 72 hrs after stimulation with inflammatory cytokines the 
percentage of microlgia showing SIRPβ1 expression was increased up to 1.7 fold after 
TNF treatment, up to 3 fold after interferon-gamma and beta treatment and up to 1.5 after 
LPS treatment.  
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Figure 4.5. Real-time RT-PCR analysis of primary microglia for 
SIRPβ1 and DAP12 demonstrated induction of SIRPβ1 by interferon-
gamma and beta after 72 hrs treatment.  
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4.6. DAP12 phosphorylation analyzed by Western 
blotting. 
C-terminal short cytoplasmic domain of SIRPβ1 interact with its adapter protein 
DAP12 molecule through phosphotyrosin-binding (PTB) domain through charged amino 
acid binding. To assess the information at translation levels, we performed some western 
blotting experiment to analyze signalling of SIRPβ1. Western blot analysis was 
performed using the NuPAGE electrophoresis system and 10% Bis-Tris gels (Invitrogen). 
The secondary antibody was horseradish peroxidase-conjugated goat anti-mouse 
polyclonal IgG and IgM (Chemicon, Germany). The Enhanced Chemiluminescence 
(ECL) Advance Western blotting Detection Kit (Amersham Biosciences) was utilized.  
We tagged the SIRPβ1 gene at the extracellular region with a flag-tag and stimulated the 
receptor with flag-tag specific antibodies. Stimulation of flag-tagged SIRPβ1 of a co-
transduced cell line 293FT stimulated phosphorylation of DAP12 as determined by 
Western blotting after immunoprecipitation of DAP12. Thus, SIRPβ1 associated with its 
signaling molecule DAP12 and stimulation of SIRPβ1 induced phosphorylation of the 
ITAM motifs. 
A)                           
Non-stimulated     Stimulated 
Phospho-tyrosin 
DAP12-GFP 
Flag-SIRPβ1 
 Actin
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B)     
 Phosphorylation of DAP12 after stimulation of SIRPβ1
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B) For quantification, optical density (OD) of the respective bands per experimental group was 
determined by ImageJ software (NIH) and normalized to the mean values of the untreated bands.  
Figure 4.6. A) Cell line 293 was lentivirally transduced with SIRPβ1 tagged at the extracellular 
side with a 3x flag epitope and with DAP12 tagged at the intracellular side with GFP. Cells were 
stimulated by coating the dish with cross-linking antibodies directed against the flag epitope. 
Protein lysates were analyzed by Western blotting with specific antibodies directed against actin, 
phosphotyrosin, DAP12-GFP or flag- SIRPβ1. Cross-linking of SIRPβ1 with the flag-specific 
antibody induced phosphorylation of DAP12.  
4.7. Increased phagocytic capacity of primary microglia 
after stimulation of SIRPβ1 
Next, we tried to establish a system for better understanding of the parameters that 
influence the microglial cells for their phagocytic activation. We tried to understand 
whether SIRPβ1 overexpression into primary microglia cells could show any functional 
influence or not. First, we lentivirally transduced flag-tagged SIRPβ1 and GFP vector in 
primary microglia; also beads were added to these cells and stimulated fSIRPβ1 with a 
flag-tag specific antibody. However, the micoglial cells showed increased phagocytic 
activity compared to control IgG antibody stimulation. (Figure 4.7)  
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A 
 
GFP-transduced microglia with beads after flag antibody stimulation 
 
 
fSIRP-transduced microglia with beads after flag antibody stimulation 
 
 
GFP-transduced microglia with beads after IgG antibody stimulation 
 
 
fSIRP-transduced microglia with beads after IgG antibody stimulation 
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Figure 4.7. Bead phagocytosis analyses 
A. Primary microglial cells were transduced with flag-tagged SIRPb1 or a 
control GFP vector. Cells were cultured on dishes coated with flag-specific 
antibodies or control antibodies. Phagocytosis of microsphere beads was 
visualized by confocal microscopy. Scale bar: 20μm. B. Primary microglial 
cells were transduced with flag-tagged SIRPb1 or a control GFP vector. 
Cells were cultured on dishes coated with flag or control specific antibodies. 
Phagocytosis of microsphere beads was analyzed and quantified by flow 
cytometry. Data are presented as mean ± SEM. Number of independent 
experiments n=12. ANOVA followed by unpaired t-test: p= <0.05 (fsirpb1 
versus gfp control)  
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4.8. Induction of experimental autoimmune 
encephalomyelitis 
A mouse model for MS was established. For this purpose, C57Bl/6 female mice 
were injected with MOG35-55 peptide and developed a progressive relapsing disease 
with a late mild remission. Disease susceptibility observed in this work is detailed in the 
table 4.8.  
 
 
 
 
 
 
Mouse strain    Incidence    Disease onset Maximal clinical  
Score 
 
C57Bl/6 64     65 ± 15%      12 ± 1 days  3 ± 0.5 
   After  
              immunization
Table 4.8. EAE disease susceptibility of C57Bl/6 mice strain. Incidence (%), 
mean time of disease onset (days) and mean maximum clinical score ± 
S.E.M. are shown for 9 independent immunization time points. 
As specified above, the incidence of the disease was between 60% and 70%. 
Onset of clinical symptoms was observed generally at days 10 to12 after immunization. 
Maximal clinical score was between 3 and 3.5 and was observed at days 4 to 5 after onset 
of the symptoms (this was the time point chosen for cell injection in the migration and 
therapeutic approaches). Only mice that showed onset (score more than 1) of clinical 
symptoms before day 14 were considered for the following experiments.  
A graph showing typical outcome data from four mice in which EAE was induced 
independently is depicted in figure 4.8. A decrease in the weight can be observed 
immediately after immunization with a second point of weight loss together with the first 
clinical manifestations. Minimal weight values coincide with worsening of the clinical 
symptoms at 4 to 5 days after onset of disease. 
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Figure 4.8. Representative diagram of mean values (± S.E.M.) of 
relative (to initial) body weight change and clinical score of 4 
independent immunized mice during the course of EAE. 
Mice usually lost weight during first 2 days after the first clinical 
symptoms. This time point coincides with worsening of the clinical 
score. This arrow represents the EAE time point achieved mice were 
sacrificed for SIRPβ1 analysis in different region. 
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 4.9. Immunohistochemistry for detection of SIRPβ1 in 
Iba1 positive microglial cells 
Next, we performed immunohistochemical analysis of formalin-fixed, paraffin-
embedded spinal cord sections. Double-immunfluorescence labelling with antibodies 
directed against SIRPβ1 and Iba1 was done. Indeed, SIRPβ1 positive cells (red) were 
identified as microglial cells showing also staining for Iba1 (green). In detail, 61 % of 
SIRPβ1 positive cells were double-immunolabelled for Iba1 (Fig. 4.9). 
 
 
 
Figure 4.9. Double-fluorescence labeling with specific antibodies directed 
against SIRPβ1 (red) and Iba1 (green) demonstrated co-localization of SIRPβ1 
and the microglial marker Iba1. 
Image was taken from the spinal cord of EAE mice at day 13 of the disease. 
Scale bar: 20μm 61% (YSEM) of Iba1 positive cells show SIRPβ1 expression. 
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4.10. Immunohistochemistry for SIRPβ1 in EAE, APP-
transgenic and control mice. 
 
SIRPβ1 expression was found in a subpopulation of microglia in brain, 
cerebellum, spinal cord as well as in spleen tissues in EAE and APP transgenic mice. 
Although some apparently resting microglia was weakly positive for SIRPβ1, most of the 
strongly stained microglia appeared to be in a reactive state as judged by morphology. 
SIRPβ1immunoreactivity was found in the brain gray matter in EAE, AD and control 
mice. To analyze the expression of SIRPβ1 in the CNS crayo sections of mice were 
stained with a rat monoclonal antibody directed against mouse SIRPβ1. All 
immunoreactive cells had a microglial-like shape. The number of SIRPβ1 positive cells 
substantially increased during the animal model of MS. Interestingly, the number of 
SIRPβ1 positive cells in APP transgenic mice was found to be >75 folds increased by 
quantitative real-time PCR analysis. Mice were immunized with the peptide myelin 
oligodendrocyte glycoprotein (MOG35-55) to induce EAE and were killed for 
immunohistochemical analysis at a clinical score of 3 (+/- 0.5). After induction of EAE, 
SIRPβ1 was detected on 37% cells/ mm2 in the spinal cord, 23% cells/ mm2 in the brain 
and 10 cells/ mm2 in the cerebellum (Fig. 4.10 E). In normal tissue very few cells were 
positive for SIRPβ1 (Fig. 4.10). In APP transgenic mice, 34% SIRPβ1 positive cells/ 
mm2 was detected in the spinal cord, 35% SIRPβ1 positive cells/ mm2 was detected in 
the brain and 14% SIRPβ1 positive cells/ mm2 was detected in the cerebellum. 
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4.11. Real-time PCR analysis of SIRPβ1 in EAE, APP-
transgenic and control mice 
 
Next, we analyzed gene transcription of SIRPβ1 and DAP12 in distinct CNS 
regions 
 
 
 
Figure 4.10. A-D SIRPβ1 is strongly expressed in the spinal cord of EAE 
 all cells/mm2 in %). 
mice and in the brain of APP transgenic mice. 
 E Quantification of positive cells in relation to
of EAE and APP mice compared with there age-matched control mice by 
quantitative real-time PCR. Gene transcript levels were normalized to the housekeeping 
gene 18s rRNA and compared to levels in the spleen of normal mice. Gene transcripts for 
SIRPβ1 and DAP12 were already detected in the spinal cord of healthy mice (Fig. 4.11). 
After induction of EAE, gene transcript levels of SIRPβ1 and DAP12 were significantly 
increased in the spinal cord as well as in the brain and cerebellum. In detail, gene 
transcripts of SIRPβ1 >5 fold (± 2) higher compared to the spleen of mice showing EAE 
with a clinical score of 3 (± 0.5) (Fig. 4.11 A and B). Most fascinating finding was 
observed in APP transgenic mice, where transcript levels of SIRPβ1 were 100 fold (±20) 
higher compared to the spleen of APP mice (Fig. 4.11 A and B).  
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4.12. Silencing of SIRPβ1 in microglia cells.  
Figure 4.11. Relative gene transcript levels were determined for SIRPβ1 (A) and 
DAP12 (B) in cerebellum, cortex, spinal cord, and spleen derived from EAE mice at 
day 13 after onset of clinical symptoms and APP transgenic mice at month 12 after 
birth. Gene transcript levels of SIRPβ1 significantly increased in the spinal cord of 
EAE mice and the cortex of APP transgenic mice, while DAP12 gene transcript levels 
increased only slightly. Data are shown as mean ± SEM. Number of independent 
experiments n= 6. ANOVA followed by unpaired t-test: p > 0.05 (SIRPβ1 EAE spinal 
cord versus cortex, cerebellum and spleen). 
To confirm knockdown of SIRPβ1 gene transcripts, microglial RNA was 
analyzed at 72 hours after transduction with the lentiviral RNA interference vector. 
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Indeed, no gene transcripts for SIRPβ1 were detected after 40 PCR cycles in reverse-
transcribed RNA of microglia after knockdown of SIRPβ1 (Fig. 4.12B). The control 
vectors plenty-GFP did not knock down SIRPβ1. Immunohistochemistry was performed 
to confirm absence of SIRPβ1 expression on microglia after knockdown. Although 
SIRPβ1 was detected by specific antibodies on control vector–transduced microglia, no 
expression of SIRPβ1 was observed after transduction of the microglia by the shSIRPβ1 
vector (Fig. 4.12 C and D). 
 A 
 
B  
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D          
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Lentiviral knock-down of SIRPβ1: A. Schematic diagram of short hairpin SIRPβ1, 
mutated short hairpin SIRPβ1 as a primary control and plenti-eGFP vector as a secondary control. 
Silencing of SIRPβ1 confirmed by RT-PCR using Sh-SIRPβ1 contained viral supernatant and 
concentrated viral particles. SIRPβ1 expression was confirmed in resting as well in a short hairpin 
SIRPβ1 transduced microglias. B. Successful knock-down of SIRPβ1 was confirmed by RT-PCR. No 
gene transcripts were detected after lentiviral knock down of SIRPβ1, while SIRPβ1 gene transcripts 
were detected without vector or after shControl vector transduction. C. SIRPβ1 silencing was 
confirmed by staining in of microglia with specific antibodies (SIRP84) directed against SIRPβ1. 
Scale bar: 20μm.D. SIRPβ1 was detected in microglia with specific antibodies (SIRP84) after 
transduction with the control vector. Scale bar: 20μm.  
4.13. Pathophysiological function of SIRPβ1 
4.13.1. Impaired phagocytosis of apoptotic neural cells and splenocytes 
after lentiviral knock-down of SIRPβ1 in primary microglia. 
Primary microglia cells were transduced with silencing and control lentiviral 
vector. Again, transduction efficiency was always >90%, leading to a loss of SIRPβ1 in 
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almost all microglial cells after transduction with the shSIRPβ1 vector. Holding 
confirmation of SIRPβ1 gene presence in sh-control microglia, we further moved to 
knock-down this gene to put on more functional information in microglia. Up-regulation 
of phagocytosis without induction of inflammatory cytokines and cytotoxic mediators 
implies clearance without an inflammatory reaction. Because microglia plays an 
important role in the removal of apoptotic neurons and splenocytes during development 
and aging, SIRPβ1 might recognize apoptotic neuronal and splenocyte membranes and 
participate in their clearance.  
To study the pathophysiological function of SIRPβ1, we used a lentiviral 
strategy to either knock-down SIRPβ1 by RNA interference and found that microglia was 
transduced with a lentiviral vector expressing either short hairpin SIRPβ1 (shSIRPβ1) 
RNA, a control vector that expressed a short hairpin scrambled sequence of SIRPβ1 
(short hairpin control [shControl]), or GFP as a control (plenti-GFP) shown us that 
SIRPβ1 is one of the essential genes for phagocytosis in microglia which clarify 
apoptotic neurons and as well as splenocytes (Fig. 4.13A and B). Neurons and 
splenocytes were labelled by a red fluorescent membrane dye and pretreated with okaidic 
acid to induce apoptosis. Microglia transduced with the control vector (shControl) (this 
work is in progress) or GFP control phagocytosed the red fluorescent–labelled apoptotic 
neuronal and splenocyte membranes fragments was detected under the fluorescence 
microscope after 24 hours (Fig. 4.13 A and B). However, an apoptotic membrane 
fragment was barely detected under the fluorescence microscope after 24 hours, when the 
SIRPβ1 receptor was knocked down in microglia (Fig. 4.13 A and B). In detail, after 24 
hours only 9.9 +1.5% (mean + SEM) of microglia showed phagocytosed neuronal 
material after knockdown of SIRPβ1, whereas 14.4 + 2.4% of microglia transduced with 
the plenty-GFPcontrol vector showed phagocytosis (Fig. 4.13 C and D). Similar result 
was observed after 24 h only 9.3 +1.5% (mean+ SEM) of microglia showed 
phagocytosed splenocyte material after knock down of SIRPβ1, whereas 21.5 + 1.4% of 
microglia transduced with the plenty-GFP-control vector showed phagocytosis (Fig. 4.13 
C and D)  
 
 
 89
Results 
A                        
 
B                       
 
 
 
 
 
Figure 4.13.1. Phagocytosis of apoptotic neural cells or splenocytes by microglia. 
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A. Microglial cells were transduced with short hairpin interference SIRPβ1 vector and 
challenged with apoptotic neural membranes labelled with a red fluorescent dye. Scale 
bar: 20μm.  
B. Microglial cells were transduced with a short hairpin interference control vector and 
challenged with apoptotic neural membranes labelled with a red fluorescent dye. Scale 
bar: 20μm.  
C and D. Statistical analysis at 24 hours after phagocytosis of apoptotic neural cells or 
splenocytes by microglia lentivirally transduced with a shSIRPβ1, shControl or GFP 
vector. Data are presented as mean +/- SEM. Number of independent experiments n=18. 
ANOVA followed by unpaired t-test: p= < 0.05 (shSIRPβ1 versus ShSIRPβ1 control and 
planti-vector control). 
4.13.2. Impaired uptake of β-amyloid after lentiviral knock-down of 
SIRPβ1 in primary microglia 
 
Primary microglia culture was maintained in a 24-well plate at a density of 3 x 
105 cells per well. Each individual experiment of primary microglia was transduced with 
pll3.7 RNA interference mediated Sh-SIRPβ1-GFP plasmid. As a control primary 
microglia was tranduced with ShSIRPβ1-Control-GFP which contains scrambled 
sequence of silencing peptide and an empty plenty-GFP plasmid, respectively. These 
respectively transduced cultures were treated with biotinylated Aβ42 peptide (10 µg/ml) 
(human amyloid β peptide 1–42 conjugated at the N-terminus with biotin) from Bachem 
(Heidelberg, Germany) overnight. To demonstrate that uptake of Aβ42 involves 
phagocytosis, cells were fixed in 4% paraformaldehyde and then permeabilized with 0.2% 
Triton-100. Fixed cells were incubated with Cy3-conjugated streptavidin (Amersham). 
These 24-well culture plates were washed with 1x Phosphate buffer saline several times 
and kept at 4°C in the dark until analysis under a laser scanning confocal microscopy 
(Leica LSC, Heidelberg, Germany). Under confocal microscopy, we observed that 
biotinylated Aß42 peptide internalization in silenced SIRPβ1 microglia showed 
respectively 30 % which is 3 fold (+/- 0.5) lower then ShSIRPβ1-control-GFP 81.30 % 
and plenty-GFP 82 %. (Independent-samples t test, p values ***<0.05). This gives very 
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clear declaration that SIRPβ1 is very purposeful receptor, which involved in amyloid 
plaques clearance by primary microglia cells in Alzheimer’s disease. 
A) 
ShSIRPβ – GFP   Aβ- cy3 
   
 
B) 
 
ShSIRPβ-control- GFP   Aβ- cy3 
   
 
Plenti Control-GFP    Aβ-cy3 
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B. Microglial cells were transduced with a short hairpin interference control 
vector and normal empty plenty vector (green) challenged with biotinilyted 
amyloid-beta membranes labeled with a red fluorescent (Cy3). Scale bar: 20μm.  
C. Statistical analysis 24 hours after phagocytosis of amyloid-beta by microglia 
lentivirally transduced with a shSIRPβ1, shControl or plenty-GFP vector. Data 
are presented as mean +/- SEM. Number of independent experiments n=9. 
ANOVA followed by unpaired t-test: *** p= < 0.05 (shSIRPβ1 versus ShSIRPβ1 
control and planti-vector control).  
Figure 4.13.2. Phagocytosis of amyloid – beta by microglia. 
A. Microglial cells were transduced with a short hairpin interference SIRPβ1 
vector (green) and challenged with biotinilyted amyloid-beta membranes labeled 
with a red fluorescent (Cy3). Scale bar: 20μm.  
 
4.13.3. Impaired uptake of basic myelin after lentiviral knock down of 
SIRPβ1 in primary microglia 
Phagocytosis by microglia/macrophages is a hallmark of the MS and 
Alzheimer’s lesions; however, the extent of tissue damage and the type of cell death will 
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dictate subsequent innate responses. Microglia/macrophages are the key effecter cells that 
remove damaged myelin sheaths by phagocytosing myelin debris. To confirm the 
biological functional activity of SIRPβ1 gene, it was analyzed with and without silencing 
in primary microglial cultures, we transduced them with shSIRPβ1-GFP and Sh SIRPβ1-
control-GFP plasmid, respectively and cells were incubated along with 2µg/ml Cy3-
labeled myelin. Myelin internalization was measured after for 6 hours of administration 
by fluorescence confocal microscopy. In general, microglia cells highest internalization 
was detectable 6 hours after myelin administration and after 24 hours, the fluorescence 
intensity of Cy3-labeled myelin decreased (Liu, 2006). Under confocal microscope, we 
observed that myelin internalization in silenced SIRPβ1 microglia shown respectively 
20.66 % which is 4 fold (+/- 0.5) lower then ShSIRPβ1-control-GFP 76.45 %. 
(Independent-samples t test, p values <0.05). 
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 ShSIRPβ – GFP   myelin- cy3  
   
 
B) 
ShSIRPβ-control-GFP  myelin-cy3 
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   Figure 4.13.3. Phagocytosis of myelin by microglia. 
A. Microglial cells were transduced with a short hairpin interference SIRPβ1 
vector (green) and challenged with cy3-conjugated myelin membranes labeled 
with a red fluorescent. Scale bar: 20μm.  
B. Microglial cells were transduced with a short hairpin interference control 
vector (green) challenged with cy3-conjugated myelin membranes labeled with 
a red fluorescent. Scale bar: 20μm.  
C. Statistical analysis at 24 hours after phagocytosis of myelin by microglia 
lentivirally transduced with a shSIRPβ1, shControl or plenty-GFP vector. 
Data are presented as mean +/- SEM. Number of independent experiments 
n=9. ANOVA followed by unpaired t-test: ** p= < 0.05 (shSIRPβ1 versus 
ShSIRPβ1 control and planti-vector control).  
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5. Discussion 
5.1. Functional characteristics of microglia 
Microglia, which may constitute as many as 12% of the cells in the CNS, were 
described by del Rio-Hortega (1932) as a distinct cell type within the CNS with 
characteristic morphology and specialized staining characteristics that differentiate them 
from other glial cells and neurons. Persistent microglial activation is an important 
constituent of neurodegenerative diseases, and this most likely contributes to neuronal 
dysfunction, injury, and loss in these diseases. Gene transfer into primary cultured 
microglia or macrophages by classical transfection procedures is very poor and results in 
very low transfection efficiency (Mack, 1998). Several factor that potentate the 
phagocytosis of apoptotic cells have been identified in vitro. These include 
glucocorticosteroids (Liu et al., 1999), ligation of the CD44 cell surface molecule (Hart et 
al., 1997), and CD36-gene transfer to semiprofessional phagocytes (Ren et al., 1995). In 
addition, different cytokines have been shown to regulate the uptake of apoptotic cells by 
human monocyte derived macrophages (Ren and Savill, 1995) and semiprofessional 
phagocytes (Walsh et al., 1999). In addition, a phagocytosis-promoting effect of in vivo 
administered GM-CSF on monocytes and polymorphonuclear leukocytes has been 
demonstrated in cancer patients (Galati et al., 2000). The understanding of microglia as 
the brain's intrinsic immune system and the understanding that chronic activation of this 
system leads to pathologic sequelae has led to the modern concept of neuroinflammation 
(Streit, 2004). As it was shown earlier by Takahashi (2005) the microglial several factors 
that potentate the phagocytosis of apoptotic cells.  
5.2. Microglial receptor SIRP-β1 involvement in 
functional understanding  
In our studies, we investigated one of such essential protein from microglial cells 
that were not much under consideration in functional understanding. We aimed to have 
evidence for the functional properties of microglial SIRPβ1 molecule to clarify its role in 
the CNS environment. For the first time, we have shown the interaction of signal 
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regulatory protein beta1 to its adapter protein DAP12, in microglia. In our studies also 
found that association between DAP12 and SIRPβ1 regulates such phenomena as 
phagocytosis in microglia.  
The immune system must be highly regulated to obtain optimal immune 
responses for the elimination of pathogens without causing undue side effects. This tight 
regulation involves complex interactions between membrane proteins and leukocytes. 
Members of the signal-regulatory protein (SIRP) family, which are expressed mainly by 
myeloid cells, provide one example of these regulatory membrane proteins. The signal 
regulatory proteins (SIRPs) are a family of transmembrane glycoproteins, which belong 
to the immunoglobulin (Ig) superfamily. The (Ig) superfamily structurally contains two 
G-type Ig subunit and one V-type Ig domain in the extracellular region on N-terminal. 
DAP12, a dimeric adapter protein that contains an ITAM activation motif that associates 
with the SIRPβ1 through its basic amino acid side chain in the C-terminal transmembrane 
region of SIRPβ1, transmits activating signals. However, the natural ligand for SIRPβ1 is 
unknown; keeping the in vivo significance of SIRPβ1 remains unresolved. It is possible 
that the heterogeneity of amino acid sequence in the extracellular region of SIRPβ1 will 
result in heterogeneous biological responses to the putative ligand of this protein. 
Microglia cells were known to express DAP12 gene and it was reported that 
TREM2, as its associated protein molecule, regulates microglia function (Takahashi, 
2005). For the first time we have shown that, SIRPβ1 is associated with DAP12 in 
microglial cells as well. We have demonstrated clearly that SIRPβ1 and DAP12 mRNA 
are present in the microglial cells, myeloid cells and splenocytes but interestingly not in 
neuron. SIRPβ1 surface expression was not only shown by real-time polymerase chain 
reaction but also by immunocytochemistry. CD11b and IbaI were used as a positive 
control, as it is known that they are microglia-macrophage specific surface markers. 
Immunolabelling of SIRPβ1 was detected as a cytoplasmic staining in cultured mircroglia 
using monoclonal antibodies directed against SIRPβ1 (SIRPβ80 and SIRPβ84, 
respectively) which was kindly provided by Japanese research group of Takashi 
Matozaki. Our microglial transduction was found to be reproducible and the expression 
was stable. Interestingly, no immunostaining of SIRPβ1 was detected in cultured neurons 
double-labelled with antibodies directed against β-tubulin-III. Nevertheless, neuronal 
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cells do express SIRPα that was identified in mouse brain as p84, which is a protein 
expressed on the surface, and this led to the first identification of a ligand for mouse 
SIRPα, namely the widely expressed cell-surface protein CD47 (Jiang, 1999). 
5.3. Activated microglial cytokines involvement in 
activation of SIRP-β1 function  
In our experiments we have found that activated microglia have shown 
upregulation of SIRPβ1. We also tried to understand why SIRPβ1 upregulates during 
microglial activation compared to resting microglia. It has been already shown by several 
groups that activated microglia have the tendency to upregulate cytokines profile. As we 
found in primary cultured microglia cytokines such as interferon-gamma (IFN-γ), 
interferon beta (IFN-β), LPS and TNF-α play major roll in SIRP-β1 upregulation, but the 
exact mechanisms by which it exerts its beneficial effects are unknown. 
Various receptors responsible for the specific recognition of targets for 
phagocytosis by macrophages have been identified (Greenberg, 2002; Platt, 1998). The 
best characterized is the Fc receptor (Fc R), which recognizes the Fc region of IgG bound 
to antigen, presented on microbial pathogens (Ravetch, 2001). The phosphorylated ITAM 
then serves as a docking site for the tyrosine kinase Syk. Downstream signalling 
mediated by phosphoinositide (PI) 3-kinase or Rho family small GTP-binding proteins 
eventually triggers phagocytosis of IgG-coated (opsonized) particles (Stephens, 2002). 
Role of SIRPβ1 was already investigated in macrophage function and examined the effect 
of SIRPβ1 engagement by specific monoclonal antibodies (mAbs) on phagocytosis as 
well as on intracellular signalling (Hayashi, 2004). SIRPβ1 was shown previously to bind 
DAP12 (Deitrich, 2000; Tomasello, 2000). Furthermore, engagement of SIRPβ1 resulted 
in the tyrosine phosphorylation of DAP12 and the subsequent recruitment of Syk to the 
SIRPβ1-DAP12 complex in RBL-2H3 cell transfectants (Deitrich, 2000; Tomasello, 
2000). We have now shown that engagement of SIRPβ1 induced the tyrosine 
phosphorylation in 293FT cells. It already elicited that the phosphorylation of Syk, a Syk 
inhibitor or kinase-negative Syk blocked the promotion of phagocytosis. A Syk inhibitor 
also blocked the activation of MAPK induced by SIRPβ1 engagement. The tyrosine 
phosphorylation of DAP12 and subsequent activation of Syk thus appear to contribute to 
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the promotion of phagocytosis by ligation of SIRPβ1 (Jackman, 1995). To analyze 
signalling of SIRPβ1, we have shown very transparently that SIRPβ1 associated with its 
signalling molecule DAP12 and stimulation of SIRPβ1 induced phosphorylation of the 
ITAM motifs. To achieve this observation, we cloned three time flag nucleotides 
sequence at the N-terminal of SIRPβ1 and then followed by GFP sequence at C-terminal 
as a fluorescent reporter gene in to the plenty-lox 3.7 viral vector background. DAP12 
was cloned into the pLenti6/V5 D-topo background. For co-transfection of these two 
vectors, Lepofectamine transfection reagent was applied to achieve efficient transfection 
of 293FT cells. Flag monoclonal antibodies were used for the phosphorylation to 
stimulate SIRPβ1 expression and after 48 hours, total protein lysate was utilized for 
western blotting analysis. It was also demonstrated that engagement of SIRPβ1 induced 
the tyrosine phosphorylation in our culture system where we shown an appropriate 
control for this experiment. 
Furthermore, the effect of SIRPβ1 stimulation on microglia in our study was 
relatively selective for phagocytosis, indicating that SIRPβ1 may activate intracellular 
pathways distinct from other innate immune receptors. We have found that phagocytosis, 
which is one of the most vital functions of microglia has shown wide interrelation and 
importance to SIRPβ1 protein. Microsphere beads phagocytosis assay has been done, 
where microglia were transduced by overexpressing SIRPβ1 by flag-tag SIRPβ1 
construct and in parallel stimulated by flag and IgG monoclonal antibodies which 
demonstrated statistically significant increase in the up-take of microsphere beads upon 
flag-antibody stimulation in activated microglia. This enables us to explain the necessity 
of SIRPβ1 protein to microglial functioning.  
5.4. Silencing of SIRP-β1 decipher unmarked 
understanding in microglial functional  
In addition, we have used a lentivirus-based vector (pLL3.7) that expresses 
RNAi-inducing shRNAs under the control of the U6 promoter (Fig.7; (Tuschl, 2002). 
This vector was engineered to co-express enhanced green fluorescent protein (EGFP) as a 
reporter gene. We showed that RNA interference for SIRPβ1 by lentiviral small hairpin 
RNAs reduced SIRPβ1 gene transcripts to levels undetectable by 40 cycles of RT-PCR in 
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transduced microglia, whereas the gene transcripts of ribosomal 18s as an endogenous 
control was not affected. Furthermore, knockdown of SIRPβ1 in microglia by RNA 
interference was confirmed by immunocytochemistry using monoclonal antibodies 
directed against SIRPβ1 (SIRPβ80 and SIRPβ84, respectively). Knockdown of SIRPβ1 in 
microglia by RNA interference allowed us to study the role of SIRPβ1 in mature and 
differentiated microglia. Although we have not observed any effect of the transduction 
procedure or the expression of nonrelated small hairpin RNAs in our control experiments, 
we cannot completely exclude that the lentiviral transduction procedure per se might 
influence the phenotype of microglia.  
5.5. Microglial receptor SIRP-β1 involvements in 
neurodegenerative disease  
Nasu-Hakola disease (NHD) is a neurodegenerative disease expressed by 
progressive dementia accompanied by bone cysts and, at random, epilepsy. It is an 
autosomal recessive hereditary disease where genetic mutation was identified in DAP12 
and its genetic defect is located at the 19q13.1 chromosome. It appears that DAP12 is 
expressed in the microglial activation and the differentiation of macrophages in the CNS 
as well at the same time, in the osteoclasts in charge of bone remodeling (Molina-
Monasterios, 2003). Gene transcripts of this DAP12-associated protein are down-
regulated in the CNS of the patients with the inflammatory NHD (Takahashi, 2007). To 
study intensively these DAP12 expressed activated microglia and their role in 
neurodegenerative disease we used postnatal three to four days old newborn mice to 
isolate microglia. We have shown the purity of microglia which isolated from mixed-glial 
cultures. 
We further moved by SIRPβ1 gene silencing to put on more functional 
information in to microglia. Neuronal loss via apoptosis is a key element in numerous 
neurodegenerative diseases. It has been shown that microglial cells phagocytose and 
degrade apoptotic material. In this study we investigated the ability of microglial cells to 
take up and degrade neuronal apoptotic material, demonstrated a SIRPβ1 receptor 
mediated pathway for the uptake, and there could be a lysosome and proteasomal 
mediated degradation of proteins from apoptotic material (figure 10). Up-regulation of 
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phagocytosis without induction of inflammatory cytokines and cytotoxic mediators 
implies clearance without an inflammatory reaction. Since we have shown that microglia 
plays an important role in the removal of apoptotic neurons and splenocytes during 
development and aging, SIRPβ1 might recognize apoptotic neuronal and splenocyte 
membranes and participate in their clearance.  
 
Figure 10. Scheme diagram of uptake and degradation of apoptotic cells by microglial cells. 
Induction of apoptotic cells were produced by okaidic acid for apoptosis in neuronal or spleen cells. 
Apoptotic cells were added to cultures of primary microglial cells. The microglia was able to recognize and 
to take up apoptotic material. The SIRPβ1 receptor played a key role in this process in our finding. 
Uptaken apoptotic cells was transported into lysosomes, and proteins were degraded by lysosomal 
proteases were shown also by (Grune, 2004). Part of the proteins from uptaken apoptotic bodies were 
degraded by the proteasomal system. Activation status of microglia influenced the uptake and degradation 
of apoptotic bodies. 
Inflammatory reactions involving microglia are characteristic of several chronic 
conditions like MS, AIDS, cerebral malaria, tuberculosis and AD. Investigators have 
devoted considerable efforts to the study of microglial involvement, particularly in MS 
and AD. In EAE, micoglial paralysis results in the substantial amelioration of the clinical 
signs and in strong reduction of the CNS inflammation. As well in the case of AD, 
reactive microglia found to colocalize with neuritic plaques in the cortical region of AD 
brains (Rogers et al., 1988). In the late neurodegeneration phase of EAE, which goes 
along with destruction of neurons, activated microglia may have a crucial role. We have 
shown in this late neurodegeneration phase of EAE and in 6 and 12 months old APP 
transgenic mice model that microglial activation, which correlate to up-regulation of 
surface membrane protein SIRPβ1 and its adapter protein DAP12 up to some extent. 
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